The 11th

Herbal and Naturopathic

International Conference

29-31 March 2019

TRADITIONAL WISDOM, FUTURE PRACTICE

Pullman Melbourne Albert Park
65 Queens Road, Albert Park VIC

REGISTER ONLINE. MEMBER DISCOUNT APPLIES.
ATTEND 3-DAYS AND YOUR CPE IS DONE FOR 2019!

www.nhaaconference.org.au

© NHAA 2018
Quality without compromise

- OptimalRx utilise Southern Cross University Phytotherapy Laboratory to independently test a selection of our herbal extracts to assure practitioners of the outstanding quality. We source exceptional quality raw material in order to provide efficacious herbal extracts to practitioners; we will not compromise on price for quality of raw materials.
- Our liquid herbal extracts are manufactured from the finest raw materials which are authenticated by independent botanists. A significant proportion of our raw material is sourced from New Zealand and the remainder from international growers.
The Australian Journal of Herbal and Naturopathic Medicine is a quarterly publication of the NHAA. The Journal publishes material on all aspects of Western herbal medicine and is a peer-reviewed journal with an Editorial Board.

ISSN 2209-119X

Members of the Editorial Board are:

Susan Arentz PhD, BHS(Hons), Adv Dip Nat, Ashfield, NSW, Australia
Joanna Harnett PhD, GradCertEd, MHlthSc, BHlthSc, Adv Dip Nat
Sydney, NSW, Australia
Erica McIntyre BSocSc(Psych)(Hons), BHSc, DipBM
Blackheath, NSW, Australia
Andrew Pengelly PhD, BA, DBM, ND
Laurel, Maryland, United States of America
Amie Steel PhD, MPH, GradCertEd, ND
Brasilia, QJ, Australia
Janelle Wheat PhD, MMedRadSc(Nuclear Medicine), MHSc(herbal medicine), BAppSc(radiography)
Wagga Wagga, NSW, Australia
Dawn Whitten BNat
Hobart, Tas, Australia
Hans Wohlman PhD, BSc
Ballina, NSW, Australia
Sue Evans PhD
Melbourne, Vic, Australia
Matthew Leach PhD, BN(Hons), ND, Dip Clin Nutr, RN
Adelaide, SA, Australia
Janet Schloss Post Grad Cert Clin Nutr, Adv Dip Health Science (Nat), Dip Nut, Dip HM, BARM
Brasilia, QJ, Australia

The Editorial Board advises on content, structure and standards for the Journal, keeping it relevant to the profession of herbal medicine. Peer reviewers will come from the Editorial Board as well as being sourced globally for their expertise in specific areas. Contributions are invited to the Journal.

The Journal is an independent academic entity and as such does not necessarily reflect the views of the NHAA.

The NHAA is a peak professional association representing appropriately qualified naturopathic and Western herbal medicine practitioners. A foundation member of the World Naturopathic Federation and founded in 1920, it is a member-based association, the oldest professional association of complementary therapists in Australia and the only national professional association specifically concerned with the practice and education of Western herbal medicine (WHM) in Australia. Our mission is to support naturopaths and Western herbal medicine practitioners to deliver excellence in healthcare in Australia and our vision is naturopathy and Western herbal medicine for the health of Australia.

Aim and scope
The Australian Journal of Herbal and Naturopathic Medicine (AJHNM) is Australia’s leading herbal publication. A thoroughly modern, peer-reviewed and clinically relevant journal, the AJHNM can trace its origins back to publications issued by the Association as long ago as the 1930s. Issued quarterly, the AJHNM publishes material on all aspects of herbal medicine including philosophy, phytochemistry, pharmacology and the clinical application of medicinal plants.

Editorial policy
- Subject material must relate to herbal medicine.
- Accepted articles become the property of the NHAA.
- Contributions are subject to peer review and editing.
- Contributions to the Australian Journal of Herbal and Naturopathic Medicine must not be submitted elsewhere.

Advertising
For advertising enquiries, please contact the NHAA office on telephone (02) 9797 2244, fax (02) 8765 0091, email nhaa@nhaa.org.au or visit www.nhaa.org.au / Publications and Products / AJHNM

Publisher Cambridge Media

Postal Address
10 Walters Drive
Osborne Park, WA 6017

Follow AJHNM on facebook

Twitter
www.twitter.com/TheNHAA

© NHAA 2018. All rights reserved. No part of this publication may be reproduced or utilised in any form whatsoever without prior written permission from the NHAA. All advertising is solely intended for the information of members and is not endorsed by the NHAA. The NHAA reserves the right to determine journal content. The views in this publication are those of the authors and may not reflect the view of the NHAA. The NHAA does not have the resources to verify the information in this publication and accepts no responsibility whatsoever for the application in whatever form of information contained in this publication. ABN 25 000 009 932
# CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Editorial: Futures and histories</strong></td>
<td>151</td>
</tr>
<tr>
<td><em>Susan Arentz</em></td>
<td></td>
</tr>
<tr>
<td><strong>Private health insurance (PHI) Reforms: Profession committee report</strong></td>
<td>152</td>
</tr>
<tr>
<td><strong>Article</strong></td>
<td></td>
</tr>
<tr>
<td><em>Interview: Ruth Trickey</em></td>
<td>154</td>
</tr>
<tr>
<td><em>Interviewer: Michelle Boyd</em></td>
<td></td>
</tr>
<tr>
<td><strong>Research</strong></td>
<td></td>
</tr>
<tr>
<td><em>Nigella sativa</em> (black seeds): Panacea or hyperbole? A critical review of experimental and clinical observations*</td>
<td>157</td>
</tr>
<tr>
<td><em>Shahid Akbar</em></td>
<td></td>
</tr>
<tr>
<td>Comparative effects of mistletoe extracts in combination with 5-Fluorouracil on viability of IEC-6 and Caco-2 intestinal epithelial cells*</td>
<td>174</td>
</tr>
<tr>
<td><em>Zahra Lotfollahia, Suzanne Mashtouba, Gordon S Howarth, Lauren C Chartier, Ljubov Simsone, Ker Y Cheahb and Susan EP Bastian</em></td>
<td></td>
</tr>
<tr>
<td><strong>Case study</strong></td>
<td></td>
</tr>
<tr>
<td>The naturopathic management of interstitial cystitis: A case study</td>
<td>180</td>
</tr>
<tr>
<td><em>Amy Taylor, David Casteleijn and Sophia Gerontakos</em></td>
<td></td>
</tr>
<tr>
<td><strong>Conference report</strong></td>
<td></td>
</tr>
<tr>
<td>A synopsis of the 2018 International Congress on Integrative Medicine and Health*</td>
<td>184</td>
</tr>
<tr>
<td><em>Bradley Leech and Jessica Bayes</em></td>
<td></td>
</tr>
<tr>
<td><strong>MedJourn</strong></td>
<td></td>
</tr>
<tr>
<td>Dairy consumption and cardiovascular disease and mortality</td>
<td>187</td>
</tr>
<tr>
<td>Low FODMAP diet and infantile colic</td>
<td>187</td>
</tr>
<tr>
<td>ART-conceived adolescents and arterial hypertension</td>
<td>188</td>
</tr>
<tr>
<td>Omega-3 supplementation during pregnancy reduces preterm births</td>
<td>188</td>
</tr>
<tr>
<td>Mediterranean diet and stroke risk</td>
<td>189</td>
</tr>
<tr>
<td>Genetics, lifestyle and stroke risk</td>
<td>189</td>
</tr>
<tr>
<td>Brain age from electroencephalogram of sleep</td>
<td>190</td>
</tr>
<tr>
<td><strong>MedPlant</strong></td>
<td></td>
</tr>
<tr>
<td>Saffron therapy for the treatment of mild/moderate age-related macular degeneration*</td>
<td>191</td>
</tr>
<tr>
<td>Effects of <em>Rhodiola rosea</em> supplementation on mental performance, physical capacity and oxidative stress biomarkers in healthy men*</td>
<td>191</td>
</tr>
<tr>
<td>Green tea as a safe treatment for non-alcoholic fatty liver disease</td>
<td>192</td>
</tr>
<tr>
<td>Saffron (<em>Crocus sativus</em>) versus duloxetine for the treatment of patients with fibromyalgia*</td>
<td>193</td>
</tr>
<tr>
<td>A comparison between the effects of ginger, pyridoxine (vitamin B6) and placebo for the treatment of the first trimester nausea and vomiting of pregnancy (NVP)</td>
<td>194</td>
</tr>
<tr>
<td>Effect of garlic supplementation on serum C-reactive protein</td>
<td>195</td>
</tr>
<tr>
<td>Effects of <em>Curcumin longa</em> on the metabolic parameters of fatty liver disease*</td>
<td>196</td>
</tr>
<tr>
<td><strong>CPE points</strong></td>
<td>197</td>
</tr>
</tbody>
</table>
Futures and histories

Susan Arentz
Editor, Australian Journal of Herbal and Naturopathic Medicine
PO Box 696, Ashfield, NSW 2131
editorajhnm@nhaa.org.au

December 2018, the eve of NHAA’s 100-year anniversary, and perfect for reflection and looking forward. This is the final issue of the year and introduces the NHAA centenary conference in March 2019, Traditional Wisdom, Future Practice. This particular conference will be a one-off event, not only because it represents 100 years of the NHAA, but also because it will host the General Assembly of the World Naturopathic Federation, and enable us to present Australian naturopathy and herbalism, and mingle with international peers, exchange and share knowledge.

A record number of abstracts have been submitted for peer review and presentation at the conference. This shows how we willingly engage with critique, and signifies a strengthening of our professions in recognising the value of peer review and transparent information. It signifies our transition towards a stable occupation and secure professional identity. I would like to congratulate all who submitted abstracts — it takes courage to put forward ideas and data, to invite feedback that may not be entirely positive, and it takes skill to redevelop and evolve our ideas; a process from which we all grow and benefit.

So where are we heading as health professionals? A round table of experts, including naturopaths and herbalists, recently explored the challenges facing complementary medicine professions in Australia¹. They aimed to identify future direction and develop leadership, action and debate. Group consensus was achieved on two main themes — these were to ensure clients remain at the centre of decisions and that evidence informing clients’ needs and safety is prioritised. These findings acknowledge clients as our biggest employers; people from the public, coming to our private practices. So what are our clients’ needs, and what is it about us that they most value and expect? The evidence provides a clear and consistent answer. Our clients seek to be involved in their own tailored health care, and they want optimal health, wellbeing and performance and help to prevent and treat chronic disease², with minimal risks in a way that fits in and complements other health care practices. They are attracted to our holistic philosophy and our natural treatments. We know this because there is high-quality, peer-reviewed, robust evidence that repeats this message³,⁴. These reasons for people’s use are key to our continued viability as health care professionals as they outline what our main employers expect, and elude to our capacity to meet unmet health needs and to our traditional and historical foundations in interdisciplinary, evidence-based practice.

Philosophically informed health care is an expressed and interesting need of our clients; I have had the privilege to delve deeper into this recently. Naturopathy and Western herbal medicine are types of holistic Western medicine. Holistic, opposite to reductionist, means including all of a person’s characteristics in a big-picture case synthesis. It requires expertise and knowledge of inter-, extra- and intracellular detail, associated organ compensation, micro and macro biology, emotional and social impacts and relationships between people and their environment. Amongst many things, it means providing simultaneous relief of symptoms and preventing disease, and providing treatment that is personal, effective, safe, affordable, accessible and meaningful.

Traditional naturopathy as a holistic practice is uniquely differentiated by six principles. This is an important point because these codified principles distinguish naturopathy from other natural medicine practices such as homeopathy and traditional Chinese medicine⁵. They communicate identity and were the sole identifying motivating factor of naturopaths’ inclusion by the World Health Organization, in the development of the Alma Ata declaration at Asanta⁶. The Alma Ata declaration emphasises the rights of all people to primary health care, prioritises primary health needs, and directly informs international and local governance, policy, political decisions and direction. An invited contribution to development of the Alma Ata recognises naturopathy as a distinct form of traditional primary health care for all people, including marginalised, at-risk and disenfranchised people.

These issues are close to many of our hearts. I look forward to hearing and sharing more about these developments at the NHAA conference in March. And I look forward to catching up with you, reflecting on our traditional wisdom and crafting our future practice. Our profession is evolving and it is essential that we contribute to and steer our way towards the future we want.
This issue presents one of our champions, Ruth Trickey. In an interview by Michelle Boyd, Ruth explains how she got into herbal medicine and reflects upon her amazing contribution. Brad Leech and Jessica Bays provide a conference report on the International Congress on Integrative Medicine and Health (ICIMH) that took place in Baltimore, America, in early 2018, with messages aligned to the round table findings mentioned earlier and the way forward. It also includes two herbal medicine articles: the first a summary of the pre-clinical and clinical evidence for \textit{Nigella sativum} and the second on the comparative effects of Mistletoe and chemotherapy on colon cancer cells. It also a case study illustrating naturopathic treatment for a woman with interstitial cystitis.

Please join me in welcoming Dr Wendy McLean as our new MedJourn, MedPlant and CPE question writer. Wendy was selected from several high-quality applicants for her critical appraisal experience. I’d like to thank all who applied; it was encouraging to receive so many high-quality applications. Wendy has contributed the MedPlant component to this issue and will take over the MedJourn from Jodie in the next issue. Thanks again, Jodie, for your support with Wendy’s transition.

I wish you all the best for the festive season, it has been a big year and this journal is really finding its feet with submissions coming from many areas of our professions. And the calibre is notably improved. Well done you! Now is time for celebration, reflection, rest and replenishment. I look forward to publishing more of your work in this peer-reviewed journal in 2019.

**References**

Private health insurance (PHI) Reforms: Profession committee report

On behalf of the Professions Committee of the NHAA Board:
David Casteleijn (Professions Committee, Chair), Tobey-Ann Pinder (Vice-President), and Natalie Cook (President)

The Honourable Greg Hunt, MP (the federal Minister for Health)’s recent decision has effectively banned private health insurers (PHIs) from covering naturopathy and Western herbal medicine, despite a high level of evidence of their efficacy and valued use in chronic conditions. The Naturopaths and Herbalists Association of Australia (NHAA) is opposed to this decision. In our opinion, these new rules do not help patients, save virtually no money, create new risks to the public, deny care that is effective, and potentially encourage care that is ineffective and/or unsafe.

Most of the issues with the new rules stem from their prohibitive nature, so, whilst the purpose was to remove public subsidies for these services, the new rules actually prohibit their provision as part of a private health insurance plan under any circumstances. What has not been made clear in the new rules is why removal of public subsidies from these therapies requires that their supply be prohibited in complying policies.

Removal of naturopathy and Western herbal medicine from private health insurance refundable status is of particular concern to the NHAA, primarily due to the anticipated impact on public safety. In the absence of statutory regulation (such as under AHPRA), naturopathy and Western herbal medicine currently operate in a self-regulated environment. A key safety lever in the current self-regulatory model is the need for practitioners to join a professional association to access PHI provider numbers in order to allow patients to claim private insurer rebates on the services rendered. In the face of inaction on the part of various governments to regulate naturopathy and Western herbal medicine, the PHIs have assumed the pseudo-regulatory role in this area by requiring practitioners be members of a professional association, to maintain current first aid training, and meet continued professional development requirements, which has acted as a steadying influence on the profession. This allows professional associations such as the NHAA to enforce standards of public safety. For instance: ‘registered’ practitioner listings, codes of conduct, education standards and educational accreditation, monitoring of compliance with first aid certification, overseeing member professional development and continuing education activities, and ensuring practising members hold appropriate levels of professional indemnity and public liability insurance.

Removal from private health insurance refundable status in relation to naturopaths (and Western herbal medicine practitioners) removes the ‘pseudo-regulatory’ function currently operating in the public interest and is likely to facilitate underqualified and non-compliant persons to practise naturopathy or Western herbal medicine with no professional checks or balances. There are already high-profile cases of misconduct by people claiming to be naturopaths, while not meeting even the most basic requirements set by some of the other representative bodies. Had there been statutory registration, cases like this would have been clearly described in the press as ‘fake naturopaths’ in similar terms to those used for other fake medical practitioners.

The NHAA is concerned the regulatory vacuum resulting from removal of PHIs for naturopaths (and Western herbal medicine practitioners) removes the ‘pseudo-regulatory’ status in relation to naturopaths (and Western herbal medicine, despite a high level of evidence of their efficacy and valued use in chronic conditions. Of the studies which were included, their positive outcomes were dismissed as not relevant to the Australian context due to the unregulated nature of the workforce.

For Western herbal medicine, the review noted that while there is a large body of research on the effects...
of individual herbal agents and remedies, the study of the real-life practice and outcomes of Western herbal medicine as a health service was separate to this research and as there were no studies of the real-life practice and outcomes of individualised Western herbal medicine as a health practice they could not reach any conclusions as to its effectiveness or potential harms.

Had naturopathy already been registered as a profession then it would not have been subject to the review in the first place. Naturopathy and Western herbal medicine have previously been assessed against the requirements for registration and found to meet the requirements. It is the NHAA’s position that the lack of statutory regulation of naturopaths and Western herbal medicine practitioners under the National Scheme (through AHPRA, as the agency that supports the National Boards to implement the National Scheme) is the key difference, to naturopaths and Western herbal medicine practitioners’ adverse treatment under the policy change (that removes the government rebate to PHIs in relation to a broad range of natural therapies). Registration under the National Scheme would address this issue and the NHAA has been, and will continue to, work to facilitate this.

In the interim, the NHAA will be working to have naturopathy and Western herbal medicine removed from the “banned list”. This is an administrative process, but it requires understanding of the issues by the Health Minister so that it becomes easier to make the change rather than to leave it as it is. This requires a grassroots campaign with naturopaths and their patients contacting their local member and the health minister to bring this to their attention and give them a reason to implement the change required. The message needs to be succinct and to the point. The NHAA will be keeping members updated with advice on practical action they can take to assist with the amendment process of the new PHI rules in the best interest of members and the public alike.

References
Introduction and thank you

Why naturopathy (herbal medicine)?

Although I liked working in the health care arena, most of my work was in hospitals and I was very dissatisfied with the way we didn’t deliver, what I later came to know of, as the holistic approach to health care. So, you could say I started in complementary medicine more for what I didn’t like about medicine rather than what I did like about naturopathy [she says with a smile].

When I first started, I believed my practice would consist of homeopathy, acupuncture and osteopathy, mostly for philosophical reasons. Along the way I realised I was a much better herbalist than a homeopath. In fact, I thought if I waited for homeopathy to work on my patients they might die in the meantime! [She giggles.]

Osteopathy was regulated so I couldn’t continue to practise as an osteopath, and I brought on a chiropractor and masseurs to look after my osteopathy patients. Acupuncture also went by the wayside when I became too busy to see my acupuncture patients twice a week, necessitating that we add acupuncturists to the team. Overall, this resulted in the expansion of the practice to a multidisciplinary clinic, which, in addition, included psychologists and other natural therapists.

Over the years herbal medicine became my true love and I studied Western and Chinese herbal medicine and Kampo.

What prompted the writing of Women, Hormones & the Menstrual Cycle?

The book was written because I was lecturing in gynaecology and obstetrics at the Southern School of Natural Therapies. Most of my students asked me if I could write a book as there was just nothing available at the time about the naturopathic treatment of these conditions. The real problem was I was only given six lectures and it was patently clear to everyone that I couldn’t do justice to these topics in 12 hours!

The book has been through three editions, four if you include the e-version. This represents a large slab of my life that has been devoted to researching and writing. In order to break the monotony, I spent three months in Austin, Texas, and two months in Columbia, South America, while rewriting the third edition. This made what would otherwise be an onerous task, much more manageable and enjoyable.

Places of clinical experience

I started my first clinic in 1978 from home. In 1980, I was one of the founding members of Carlton Healing Centre and I also started a small clinic in Clifton Hill, called Clifton Hill Natural Health Centre. This clinic was expanded over the years to accommodate the increasing numbers of practitioners who needed to work there, to satisfy the demand for our professional services.

In 2000, I moved my clinic to Fairfield to an even larger premises and we became known as Melbourne Holistic Health Group. It was here that I really started to get involved in working collaboratively with other medical professionals to attempt to gain the best outcomes for patients. I was also invited to work in a multidisciplinary medical clinic for the treatment of obesity; this proved to be stimulating and challenging work.

What was your experience of working with gynaecologists?

There were many occasions when I was asked to present to groups of medical practitioners about the use of herbal medicine in gynaecology. In the early days, gynaecologists were interested in the use of *Vitex agnus-castus* as there was evidence for this herb’s efficacy in premenstrual syndrome (PMS). At these talks I was continually amazed by how interested they were about the wider scope of herbal medicine.

Over time, relationships developed, many had read my book, and they became more and more informed about herbal medicine. For example, when I went to talk to a self-help group at the Royal Women’s Hospital, the gynaecologist who was speaking alongside me gave a full evidence-based talk on why herbal medicine was a suitable addition to these women’s health care. From the inception of my practice in the early ’80s, referrals were common, particularly for complaints for which medicine had little to offer. This expanded over the years to include more and more specialists and for more and more different types of complaints.
I also regularly presented with gynaecologists to self-help groups, principally on polycystic ovary syndrome (PCOS), endometriosis, infertility and menopause.

Three strengths of naturopathy

The provision of holistic health care and all this entails

This has always been an important aspect of my treatment. Years ago, a gynaecologist remarked that we (naturopaths) continue to see patients for years instead of curing them and sending them on their way. My response, given that the only way he was going to understand holistic medicine, was that we worked similarly to the old-fashioned country doctor, who was responsible for every aspect of health for all family members, from birth to death. The gynaecologist thought about this and then apologised saying that this aspect was sadly missing from modern medicine, which now largely focused on conditions rather than patients.

Safer interventions

Lifestyle correction and natural remedies are overall safer than their medical counterparts.

Unique treatment options

There are some herbal medicines that provide treatments for conditions that medicine has no answer for. For example, Vitex in certain types of premature ovarian failure.

Three areas (of the profession) in need of development

Delaying appropriate intervention

More attention needs to be given to the potential harm that can be done when practitioners undertake the treatment of patients with conditions that may not be suitably responsive to natural therapies alone.

Mentoring

The profession needs to have a more cohesive approach to mentoring. I have done this throughout my career without ever charging for this service, since I believe experienced practitioners have an obligation to pass on their knowledge to students and the less experienced. This benefits not only individual practitioners but improves the overall development of the profession.

Diagnosis, particularly differential diagnosis

One of the most common questions I would ask of practitioners learning from me was “What else could this be?” And it was, by far, the weakest aspect in their knowledge. Not only did they not know what it could be, but they had not even thought to consider a differential diagnosis.

Future hopes and dreams

Future hopes

That the world at large wakes up and realises what a mess we are in and that we have strong leaders who take global warming and the associated problems seriously. At an individual level, that we all strive to protect and heal the planet in the same way that we do for our patients.

Dreams

To grow veggies and herbs, and to contribute to my community, especially in relation to the housing crisis.

Ruth then walked me around her tranquil garden and gathered a bunch of basil, zucchinis and cucumber for me to take home.
P2 Detox
Phase II Detox Support

A comprehensive formula containing Broccoli sprouts, Turmeric, amino acids and other supportive nutrients to support Phase II liver detoxification.

- Contains Broccoli sprouts with 15 times more glucoraphanin (a precursor to sulphoraphane) than mature Broccoli for anti-oxidant support.
- Delivers high levels of taurine, cysteine, methionine and glutamine to help maintain glutathione levels.
- Contains taurine and glycine to support lipid emulsification.

For your copy of the MediHerb® Prepare-Detox-Protect Program visit mediherb.com.au
Nigella sativa (black seeds): Panacea or hyperbole? A critical review of experimental and clinical observations

Shahid Akbar MD, PhD
Former Professor of Pharmacology, Medical University of the Americas, Nevis, and Department of Pharmacology, Director, College of Pharmacy Research Center, Qassim University, Buraidah, Saudi Arabia

Contact information
Dr Shahid Akbar, 2651 Eagle Rock Circle, Stockton, CA 95209, USA
Email shahidakbar@sbcglobal.net  drakbarmdphd@gmail.com

Abstract
Introduction: Black seeds, also called black cumin, and known as Habb-es-Sauda and Habbat-ul-Barakah (Seeds of Blessing) in Arabic, are reverently used by Muslims all over the world, because their usefulness and health benefits are mentioned in a Hadith of the Prophet Mohammad (PBUH). All ancient and modern cultures, be it Greek, Roman, Egyptian, Mediterranean, Hindu or others have used black seeds in one or the other form since millennia.

Purpose: This review is an attempt to critically evaluate the experimental and clinical evidence in support of the health benefit claims about black seeds or lack thereof. The major focus of this review was on studies that involved whole seeds, powdered seeds, their aqueous decoction/extract or black seeds oil, administered orally. Reports that did not specify the nature of the extract used in the studies, or studies involving isolated constituents were generally avoided.

Results: In most clinical trials, a daily dose of 2 g of black seeds was found optimum to achieve health benefits, including on blood glucose, lipid profile, inflammation, gastrointestinal symptoms and the central nervous system (CNS). Most of the effects on the CNS were reported by the volatile oil. Other positive results reported in clinical trials have not been reproduced or expanded to validate their outcomes.

Discussion: A number of positive results were achieved in many clinical trials on black seeds, but a paucity of clinical studies reproducing these reported clinical benefits necessitates clinical trials in more diverse populations, of longer duration, and involving a significantly higher number of patients to establish the reproducibility.

Keywords: Nigella sativa, black seed, black cumin, Habb-es-Sauda, Habbat-ul-Barakah

Introduction
Despite breath-taking advances in modern medicine we are still grappling to find cures for the most common diseases of our times, like diabetes and hypertension, and the increasing incidences of various types of cancer that affect populations in every part of the globe. Since natural or plant-based drugs have been used by humans to address their health care needs for millennia and are still depended upon by large sections of societies throughout the world, they become our focus of attention when modern medicine fails to provide sufficient, safe, inexpensive or long-term answers. Black seeds, also called black cumin, are known as Habb-es-Sauda, and Habbat-ul-Barakah (Seeds of Blessing) in Arabic and are reverently used by Muslims all over the world, both medicinally and as a spice, because the Prophet Muhammad (Peace Be Upon Him) is quoted to have said “Use black seed regularly, since it is a cure for every disease except death”1. Black cumin are the seeds of an annual flowering plant, Nigella sativa, native to the Mediterranean, and south and south-west Asian countries, belonging to the family Ranunculaceae. Use of black cumin seeds dates back to the ancient Egyptians, Greeks, and Romans. Hippocrates and Dioscorides mentioned them as Melanthion, and Pliny called them Gith2. Black cumin seeds were found in the tomb of the Egyptian Pharaoh, Tutankhamen (also spelled as Tutankhamun), who ruled Egypt c. 1332–1323 BC3, and were also recovered in north-central Turkey from a pilgrim flask of the Old Hittite period of Boyali Höyük, dating from around 1650 BC4. “Muslim physicians of Greco-Arab medicine in India describe them as heating, attenuant, suppurative, detergent and diuretic, and believe that they increase menstrual flow and the secretion of milk, and stimulate uterine activity”2. They are also claimed to have been used to treat nervous system diseases such as memory impairment, epilepsy, neurotoxicity, and pain5. Hindu physicians of India use them with other aromatics and Plumbago root in dyspepsia, loss of appetite, diarrhoea and intermittent fevers, and a decoction of the seeds is given after delivery to stimulate uterine contraction and to stimulate milk secretion6. In India, Arab countries, Europe and Iran, the seeds and oil are also traditionally used in the treatment of asthma, hypertension, diabetes, inflammation, tumour, cough, bronchitis, headache, eczema, fever, dizziness, gastrointestinal disturbances, impotence, painful menstruation, flu, and as a carminative, diuretic and anti-parasitic agent7. The seeds are one of the most frequently...
used plant medicine to treat diabetes and hypertension in the south-eastern Moroccan folk medicine, and more than 70% of Jordanian diabetic patients use them as adjunct to conventional therapy and 80% of them with the knowledge of their physicians. This review is intended to evaluate the published experimental and clinical studies, listed on PubMed, to determine if the claims made about health benefits of black seeds stand scientific scrutiny.

**Methodology**

Published articles in English listed on PubMed until 2018 were included in the review. The focus of this review was studies, both animal and human clinical trials, that used orally, either whole seeds, powdered seeds, their aqueous decoction/extract or the oil, to reconcile with the common forms of traditional human use. Studies on organic solvent extracts, routes of administration other than oral, or isolated individual constituents, such as thymoquinone (TQ), the major active constituent of the oil, have been sparingly used where relevant or in cases a comparison was needed. Similarly, in vitro studies have rarely been mentioned, except only where their inclusion was relevant to complement other findings. The nationalities of the patients involved in clinical studies have been identified for the simple reason that the racial differences, cultural and psychological influences, and dietary habits may affect the observed outcomes, and observations in one set of individuals may, at times, not be replicated in other individuals. Also, the chemical contents of the seeds and volatile oil (VO) from various countries and within a country may vary remarkably and produce variation in results.

**Results**

**Chemical constituents**

The seeds are reported to contain 36%–38% fixed oil, proteins, alkaloids, saponin, and 0.4%–2.5% essential oil. Alkaloids, anthraquinones, flavonoids, phenolic compounds, proteins, carbohydrates, saponins, lipids, sterols and tannins have also been reported present in aqueous and methanol extracts. The alkaloidal fraction include indazole-type alkaloids, such as nigellidine and nigelanoid, and dolabellane-type diterpene alkaloids, such as nigellamines, and various triterpene glycosides, such as α-hederin, and steroidal glucoside, have also been isolated from the seeds. The seeds contain both the fixed and volatile oil, and thymoquinone is present in both oils. The chemical composition of VO of seeds from various countries and within a particular country has been reported to vary remarkably. Volatile oil of seeds from India contained 47 compounds, of which TQ, dithymoquinone, thymohydroquinone and thymol were the major phenolic compounds, varying dependent upon extraction method; TQ and p-cymene were the major constituents of the 38 volatile compounds identified in seed oil from Turkey; but TQ (62.17%), carvacrol (16.84%), 2-methyl-5-Prop-2-enyldihydroquinone (8.29%), dihydro-thymoquinone (6.99%), monoterpenes (3.11%) and terpin-4-en-1-ol (2.07%) were identified as major constituents of VO of seeds from Morocco. However, major variations were reported from Iran; while trans-anethole (38.3%), p-cymene (14.8%), limonene (4.3%) and carvone (4.0%) were identified as major compounds in VO out of the 32 compounds by Nickavar et al., TQ (42.4%), p-cymene (14.1%), carvacrol (10.3%) and longifolene (6.1%) were reported as the major components by Mahmoudvand and associates; whereas, p-cymene (58.2%), α-thujene (11.2%), carvacrol (3.63%) and longifolene (3.32%) were the main components out of 14 identified in the steam distilled VO, all from Iran.

**Experimental studies**

The results of experimental studies are tabulated in Table 1.

**Anticancer activity**

The seeds have been reported to exert anti-proliferative, pro-apoptotic, cytotoxic, antimutagenic, antiangiostatic, and NK cells cytotoxic activity enhancing effects against various primary cancer cells and cancer cell lines. Black seeds supplemented diet inhibited DNA damage in azoxymethane-induced colon cancer in rats, and oral treatment of rats with seeds significantly suppressed ferric nitrilotriacetate-induced renal carcinogenesis, and with honey protected 100% against methylnitrosourea (MN)-induced oxidative stress and renal carcinogenesis in rats. Topical application of seed extract delayed the onset of dimethylbenz [a] anthracene (DMBA)-induced skin papillomas, and intraperitoneal administration significantly reduced the incidence of 20-methylcholanthrene (MCA)-induced soft tissue sarcoma in mice. The VO also inhibited 1,2-dimethylhydrazine (DMH)-induced colon carcinogenesis of rats in the post-initiation stage, with suppression of cell proliferation in the colonic mucosa, and the seed oil treatment decreased the expression of Brca1, Brca2, Ig-1 and P53 mutations in mammary tissues of female rats with DMBA-induced breast cancer and reduced the activities of tumour markers. While the MCF-7 breast cancer cells exposed to alcohol seed extract were completely inactivated, aqueous extract showed weak activity. Injection of the VO into the tumour also significantly inhibited solid tumour development. TQ inhibited DNA synthesis, proliferation, and viability of cancerous prostate epithelial cells by down-regulating androgen receptors and E2F-1, a regulator of cell proliferation and viability, without affecting the noncancerous cells, inhibited benzo(a)pyrene (BP)-induced forestomach carcinogenesis, prevented MCA-induced fibrosarcoma tumours, and blocked tumour angiogenesis in a xenograft human prostate cancer in mice. TQ is reported to exert anticancer effects through activation of tumour suppressor gene, phase II gene/enzymes, peroxisome proliferator-activated receptors (PPARs), inactivation of angiogenesis and anti-inflammatory gene, and induction of apoptosis.
Table 1: Brief descriptions of experimental studies on black seeds (*Nigella sativa*)

<table>
<thead>
<tr>
<th>Activity</th>
<th>Type of study</th>
<th>Form and route of use</th>
<th>Model/Animals</th>
<th>Results</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticancer</td>
<td>In vitro</td>
<td>Alcohol seed extract</td>
<td>MCF-7 breast cancer cells</td>
<td>Anti-proliferative, and cytotoxic effect</td>
<td>Farah and Begum, 2003</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>Seed oil (oral)</td>
<td>DMBA-induced breast cancer in female rats</td>
<td>Decreased expression of the Brca1, Brca2</td>
<td>Linjawi et al., 2015</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>Dietary seed supplementation</td>
<td>Azoxymethane-induced colon cancer in rats</td>
<td>Prevented DNA damage</td>
<td>Al-Johar et al., 2008</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>Intra-tumour injection of VO</td>
<td>Solid grafted tumour in mice</td>
<td>Significantly inhibited tumour development, liver metastasis and improved survival</td>
<td>Alt Mbarek et al., 2007</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>Dietary seed supplementation</td>
<td>Nitrilotriacetate-induced renal carcinogenesis in rats</td>
<td>Suppressed oxidative stress, and hyperproliferative response</td>
<td>Khan and Sultana, 2005</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>VO (oral)</td>
<td>DMH-induced colon carcinogenesis in rats</td>
<td>Inhibited colon carcinogenesis and colonic mucosa cell proliferation</td>
<td>Salim and Fukushima, 2003</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>Powdered seeds 0.2 g/day (oral)</td>
<td>MNU-induced carcinogenesis in rats</td>
<td>Protected against oxidative stress and carcinogenesis by 80%</td>
<td>Mabrouk et al., 2002</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>Topical application of seed extract</td>
<td>DMBA-induced skin papillomas in mice</td>
<td>Delayed onset of skin papillomas</td>
<td>Salomi et al., 1991</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>Seed extract (i.p.)</td>
<td>MCA-induced soft tissue sarcoma in mice</td>
<td>Reduced the incidence of soft tissue sarcoma</td>
<td>Salomi et al., 1991</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>TQ (oral)</td>
<td>BP-induced forestomach carcinogenesis in mice</td>
<td>Significant inhibition of tumourigenesis</td>
<td>Badary et al., 1999</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>TQ (oral)</td>
<td>MCA-induced fibrosarcoma in mice</td>
<td>Significantly prevented fibrosarcoma development</td>
<td>Badary et al., 2001</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>TQ (oral)</td>
<td>Human prostate cancer xenograft in mice</td>
<td>Blocked tumour angiogenesis</td>
<td>Yi et al., 2008</td>
</tr>
<tr>
<td>Antidiabetic</td>
<td>In vitro</td>
<td>Aqueous seed extract</td>
<td>Isolated rat jejunum</td>
<td>Inhibited sodium-dependent glucose transport</td>
<td>Meddah et al., 2009</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>Aqueous seed extract (oral)</td>
<td>Normal rats</td>
<td>Improves glucose tolerance</td>
<td>Meddah et al., 2009</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>Aqueous seed extract (oral)</td>
<td>Diabetic rats</td>
<td>Lowered blood glucose, and prevented lipid peroxidation-induced liver damage</td>
<td>Meral et al., 2001</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>Fixed oil (oral)</td>
<td>Normal rats</td>
<td>Lowered blood glucose, TC, and TGs</td>
<td>Zaoui et al., 2002</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>Fixed and VO (oral and i.p.)</td>
<td>Diabetic rats</td>
<td>Reduced oxidative stress</td>
<td>Kanter et al., 2004; Sultan et al., 2014</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>VO (oral and i.p.)</td>
<td>Diabetic rats</td>
<td>Lowered blood glucose, increased phagocytic activity and cell regeneration</td>
<td>Farah et al., 2002; 2004; Kanter et al., 2003, 2009</td>
</tr>
<tr>
<td>Antihyperlipidaemic</td>
<td>In vivo</td>
<td>Dietary seed supplementation</td>
<td>Normal and hypercholesterolaemic rats</td>
<td>Lowered TC, LDL-C, TGs, and improved antioxidants activity</td>
<td>Kocyigit et al., 2009; Muneera et al., 2015; Al-Rasheed et al., 2014</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>Diet supplemented with seed powder, VO</td>
<td>Hypercholesterolaemic rabbits</td>
<td>Lowered TC, LDL-C, increased HDL-C, and inhibited aortic plaque formation</td>
<td>Al-Naqeep et al., 2011</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>Fixed oil (oral)</td>
<td>Normal rats</td>
<td>Lowered blood glucose, TC, TGs, WBCs, and platelets</td>
<td>Zaoui et al., 2002a,b</td>
</tr>
<tr>
<td>Analgesic/Anti-inflammatory</td>
<td>In vivo</td>
<td>Aqueous seed suspension (oral)</td>
<td>Paw oedema in rats; hot plate in mice</td>
<td>Antinociceptive, and anti-inflammatory effects</td>
<td>Al-Ghamdi, 2001</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>VO (oral), TQ (oral, i.p., i.c.v.)</td>
<td>Hot-plate, tail-pinch, acetic acid-writhing and formalin tests</td>
<td>Antinociceptive effect</td>
<td>Abdel-Fattah et al., 2000</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>TQ (i.p.)</td>
<td>Airway inflammation, adjuvant-arthritis,</td>
<td>Anti-inflammatory effects</td>
<td>Abbas et al., 2005; El Mezayen et al., 2006; Tekoeoglu et al., 2007</td>
</tr>
<tr>
<td></td>
<td>In vitro</td>
<td>Fixed oil and TQ</td>
<td>Peritoneal leukocytes</td>
<td>Inhibition of COX and 5-LOX</td>
<td>Houghton et al., 1995</td>
</tr>
<tr>
<td>Activity</td>
<td>Type of study</td>
<td>Form and route of use</td>
<td>Model/Animals</td>
<td>Results</td>
<td>Reference(s)</td>
</tr>
<tr>
<td>-------------------</td>
<td>---------------</td>
<td>-----------------------</td>
<td>---------------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Antimicrobial</strong></td>
<td>In vitro</td>
<td>Aqueous extract</td>
<td></td>
<td>More effective against multiple antibiotics-resistant Gram-negative isolates</td>
<td>Morsi, 2000</td>
</tr>
<tr>
<td></td>
<td>In vitro</td>
<td>VO</td>
<td></td>
<td>Strongly active against Aspergillus fumigatus, T. mentagrophytes, M. canis and M. gypseum</td>
<td>Islam et al., 1989; Mahmoudvand et al., 2014</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>VO (i.p.)</td>
<td>Murine cytomegalovirus (MCMV) infected BALB/c mice</td>
<td>Inhibited MCMV titres in spleen and liver, increased serum IFN-gamma</td>
<td>Salem et al., 2000</td>
</tr>
<tr>
<td><strong>Cardiovascular</strong></td>
<td>In vivo</td>
<td>Dietary seed supplementation</td>
<td>Normal rats</td>
<td>Cardiac hypertrophy, improved cardiac contractility and performance</td>
<td>Ai-Hariri et al., 2009; El-Bahai et al., 2009; Yar et al., 2008</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>Oral seed powder for 12 weeks</td>
<td>Normal rats</td>
<td>Increased resistance to oxidative stress and I/R damage</td>
<td>Seif, 2013</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>Aqueous seed extract (b.p.)</td>
<td>Normal rats</td>
<td>Diuresis, natriuresis and kaliuresis</td>
<td>Asif et al., 2014</td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td>In vivo</td>
<td>VO (oral)</td>
<td>Normal rats</td>
<td>Antidepressant effect, improved learning and memory, prevented morphine tolerance and dependence</td>
<td>Perveen et al., 2013; Sahak et al., 2013; Abdel-Zaher et al., 2010</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>VO (oral)</td>
<td>Normal and diabetic rats</td>
<td>Prevented oxidative brain damage and diabetic neuropathy</td>
<td>Ezz et al., 2011; Ihan et al., 2005; Hosseinzadeh et al., 2007; Kanter et al., 2006, Kanter, 2008</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>VO (oral)</td>
<td>Normal rats</td>
<td>Prevented haloperidol-induced movement disorders and dyskinesia</td>
<td>Malik et al., 2016</td>
</tr>
<tr>
<td><strong>GIT</strong></td>
<td>In vivo</td>
<td>VO (oral)</td>
<td>Normal rats</td>
<td>Reduced experimental gastric ulcers, gastric oxidative stress, and protected against TNBS-colitis</td>
<td>Bukhari et al., 2011; El-Dakhakhny et al., 2000; Kanter et al., 2005, 2006; El-Ahmar et al., 2003; Isik et al., 2011</td>
</tr>
<tr>
<td><strong>Liver</strong></td>
<td>In vivo</td>
<td>Dietary seed supplementation</td>
<td>Normal rats</td>
<td>Protected against hepatotoxic agents</td>
<td>Farrag et al., 2007; Hassan et al., 2012; Jaswal et al., 2016</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>Water suspension and extract of seeds</td>
<td>Normal rats</td>
<td>Protected against CCl4-induced hepatotoxicity</td>
<td>Al-Ghamdi, 2003; Jaswal and Shukla, 2015</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>VO (oral)</td>
<td>Normal rats</td>
<td>Protected against CCl4-, d-galactosamine, hypervitaminosis A hepatotoxicity, and I/R injury</td>
<td>Al-Seenii et al., 2016; Meral and Kanter, 2003; Türkdoğan et al., 2003; Ibrahim et al., 2008; et-Dakhakhny et al., 2000; Al-Suhaimi, 2012; Yildiz et al., 2008</td>
</tr>
<tr>
<td><strong>Kidneys</strong></td>
<td>In vivo</td>
<td>Powdered seeds</td>
<td>Normal rats</td>
<td>Protected against I/R injury</td>
<td>Mosavii, 2015; Mosavii and Mohajeri, 2014</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>VO (oral)</td>
<td>Normal and diabetic rats</td>
<td>Ameliorated gentamicin, sodium nitrite, bromobenzene acetaminophen, and cyclosporine nephrotoxicity, and protected against I/R injury and diabetic nephropathy</td>
<td>Ali, 2004; Saleem et al., 2012; Yaman and Balici, 2010; Al-Gayyar et al., 2016; Hamed et al., 2013; Ahmed and El-Mottaleb, 2013; Ul et al., 2008; Bayrak et al., 2008; Havakhan et al., 2014; Yildiz et al., 2010; Yusususawad and Chaiyabutr, 2011</td>
</tr>
<tr>
<td><strong>Reproduction</strong></td>
<td>In vivo</td>
<td>Dietary seed supplementation</td>
<td>Normal rats</td>
<td>Increased testosterone level</td>
<td>Mohajeri et al., 2015</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>Low dose seeds (oral)</td>
<td>Ovariectomised rats</td>
<td>Oestrogenic like effects on reproductive organs</td>
<td>Parhizkar et al., 2016</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>Aqueous extract</td>
<td>Normal rats</td>
<td>Increased milk production</td>
<td>Agrawala et al., 1971; Hosseinzadeh et al., 2013</td>
</tr>
<tr>
<td></td>
<td>In vivo</td>
<td>VO (oral)</td>
<td>Normal rats</td>
<td>Improved semen quality, and sperm motility</td>
<td>Mosbah et al., 2016; Cho Ping et al., 2014</td>
</tr>
</tbody>
</table>

VO: Volatile oil; BP: Benzo(a)pyrene; CCl4: Carbon tetrachloride; COX: Cyclooxygenase; DMBA: Dimethylbenz[a]anthracene; DMH: Dimethylhydrazine; I/R: Ischaemia/Reperfusion 5-LOX: Lipoxygenase; MCA: Methylcholanthrene; MNU: MethylNitrrosourea; TC: Total cholesterol; TGs: Triglycerides
Antihyperglycaemic effects

The aqueous seed extract (AE) was shown to inhibit in vitro sodium-dependent glucose transport across isolated rat jejunum, and in vivo improved glucose tolerance in normal rats after six weeks of treatment (2g/kg/d), comparable to metformin39, reduced blood glucose and malonaldehyde (MDA) concentrations, increased glutathione (GSH) level and prevented lipid peroxidation-induced liver damage in diabetic rabbits40. Oral administration of fixed oil to normal rats for 12 weeks significantly decreased glucose levels, serum cholesterol (TC), and triglycerides (TGs), and leukocyte and platelet counts41. The fixed and VO significantly improved diabetes-induced oxidative stress in rats42,43, and the VO significantly reduced blood glucose, increased antioxidant enzymes activity44, significantly increased phagocytic activity of peritoneal macrophages of diabetic hamsters, at least partly, from a stimulatory effect on β-cells function44-45, caused a partial regeneration/proliferation of pancreatic β-cells in diabetic rats42-46, and preserved β-cells integrity47; an extrapancreatic component is suggested for the hypoglycemic effect because the fall in blood glucose is not parallel to the stimulated insulin release48.

Antihyperlipidaemic effects

The positive effects on lipid profile were evident when diet supplemented with seeds significantly decreased TC, LDL-cholesterol (LDL-C) and TGs in normal49, and hypercholesterolaemic rats40, and powdered seeds highly significantly reduced serum LDL-C and TGs, and improved antioxidant enzymes activities in rats with fructose-induced metabolic syndrome51. Hypercholesterolaemic rabbits supplemented in diet with seed powder and VO had significantly reduced TC and LDL-C and enhanced HDL-cholesterol (HDL-C) levels and significantly inhibited aortic plaque formation52. One-week administration of the seed oil afforded significant and strong protection (94.5%) against methionine-induced hyperhomocysteinemia and the associated changes in triglycerides, lipid peroxidation, and cholesterol53. Twelve weeks oral treatment of rats with fixed oil significantly decreased serum TC, TGs and glucose levels, slowed body weight gain, significantly increased haematocrit and hemoglobin levels, but significantly reduced leukocyte and platelet counts41,54.

Analgesic and anti-inflammatory effects

The AE exhibited both analgesic and anti-inflammatory activities55; whereas ethanol extract is reported to produce anti-inflammatory effect of longer duration46 but a lesser analgesic effect than dicylenae57. Oral administration of the VO produced dose-dependent analgesic activity, that was significantly blocked by naloxone, indicating the possibility of involvement of opioid mechanism58, but only i.p. dose exhibited significant anti-inflammatory effect59. Both fixed oil and TQ inhibited cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) pathways in rat stimulated peritoneal leukocytes, significantly reducing synthesis of thromboxane B2 and leukotriene B4, respectively. However, the inhibition of eicosanoid generation rendered by the fixed oil was greater than was expected from its TQ contents, an indication that constituent(s) other than TQ may contribute to the anti-inflammatory effect60. Pretreatment with TQ (i.p.) attenuated ovalbumin-induced airway inflammation in mice61,62, suppressed adjuvant-induced arthritis in rats63, and potently inhibited the formation of leukotrienes in blood cells64,65.

Antimicrobial activity

The AE was more effective against multiple antibiotics-resistant Gram negative isolates than the Gram positive ones65, and Candida albicans66. Aqueous infusion of ground seeds from Hadramout (Yemen) was reportedly more effective in inhibiting in vitro growth of Staphylococcus aureus (S. aureus) than the ground seeds from Ethiopia, but without any effect on Escherichia coli (E. coli) or Enterobacter67. Ethanol seed extract was reported active against various strains of methicillin-resistant S. aureus (MRSA)68, and against Salmonella typhi (S. typhi), S. aureus, Bacillus subtilis, Bacillus cereus, Klebsiella pneumoniae, E. coli, Xanthomonas, Salmonella heidelberg, Clostridium, Aspergillus niger, Aspergillus flavus, Alternaria alternata and Penicillium69. VO was significantly active against S. aureus, Micrococcus lysodeikticus and Sarcina lutea, and moderately active against E. coli, S. typhi, Pseudomonas aeruginosa, B. subtilis and C. albicans, with thymohydroquinone identified as the active principle70, and strongly active against Aspergillus fumigatus71, on dermatophytes, Trichophyton mentagrophytes, Microsporum canis and Microsporum gypseum24. Nearly half of the 19 isolates of multidrug resistant S. aureus, from Nigerian diabetic patient’s wounds were susceptible to different concentrations N. sativa oil72. Alpha-zam, an indigenous Nigerian formulation of N. sativa, selectively inhibits hepatitis C virus (HCV) replication73. Oral administration of the oil was protective against hematological and biochemical changes in schistosomiasis-infected mice and markedly improved the antioxidant capacity74, whereas administration of VO (i.p.) to BALB/c mice infected with a susceptible strain of murine cytomegalovirus (MCMV), strikingly inhibited the MCMV titres in spleen and liver, and increased serum level of IFN-gamma75.

Cardiovascular effects

Dietary supplementation of normal rats with seeds produced a homogeneous cardiac hypertrophy and enhanced cardiac contractility and improved cardiac performance76-78, preserved and augmented exercise-induced physiological cardiac hypertrophy79, and significantly increased vascular endothelial growth factor (VEGF) in heart similar to aerobic exercise, that could potentially induce coronary angiogenesis80. However, both aqueous and macerated extracts significantly reduced heart rate (HR) and contractility of isolated
guinea pig heart, due to calcium channel blocking effect that was greater than nifedipine101,102, and hearts isolated from rats administered seed powder orally for 12 weeks showed resistance to oxidative stress and damage due to ischaemia/reperfusion (I/R) injury, further reinforcing the positive effect on heart103. Seeds incorporated in rats’ diet for four weeks induced significant hyper-fibrinogenemia, while doubling the dose for two weeks significantly, but transiently prolonged prothrombin time and reduced thrombin time104. Intravenous administration of aqueous seed extract lowered mean arterial pressure (MAP) with a significant decrease in HR in normal rats, that was partly dependent on endothelium85. Oral administration of oil prevented increase in systolic blood pressure (SBP) of L-NAME-induced hypertensive rats, along with reduction in cardiac lipid peroxidation product, NADPH of L-NAME-induced hypertensive rats, along with arterial BP and HR lowering reduction in cardiac lipid peroxidation product, NADPH of L-NAME-induced hypertensive rats, along with arterial BP and HR lowering. The arterial BP and HR lowering reduction in cardiac lipid peroxidation product, NADPH of L-NAME-induced hypertensive rats, along with arterial BP and HR lowering could also contribute to the hypotensive effect.

CNS effects

Aqueous extract of defatted seeds exhibited potent CNS depressant and analgesic effects97, the AE also showed anxiolytic activity98, and the VO produced antidepressant activity with increase in brain 5-HT levels and decreased 5-HT turnover in rats99. Pretreatment with VO for 20 days improved learning and memory of normal rats100, and repeated administration of VO attenuated the development of tolerance and dependence to morphine101, probably through some mechanism other than opioid receptors. The VO effectively prevented brain oxidative injury due to experimental seizures, better than valproate101,102, ameliorated brain ischaemia and spinal cord injury-induced oxidative damage97,99, and diabetic neuropathy86, but failed to significantly affect pilocarpine-induced spontaneous recurrent seizures in rats99. Pretreatment with hydro-alcohol extract improved learning and memory in rats100 and prevented hippocampal neural damage in pentylentetrazole-induced repeated seizures in rats101, protected against scopolamine-induced spatial memory impairment102, and against hypothyroidism-associated learning and memory weakening during neonatal and juvenile growth in rats103. Treatment of aged female rats with VO for two months improved the structure and the thickness of olfactory epithelium, that tends to reduce in thickness due to ageing104. Co-administration of VO to rats significantly protected against haloperidol-induced EPS-like effects, including movement disorders and oral dyskinesia105. Chronic toluene exposure caused neurodegeneration in the frontal cortex and brain stem of rats was completely prevented by concurrent oral administration of seeds106 and thymoquinone107.

Gastroprotective effects

Pretreatment with seeds and VO significantly reduced experimental gastric ulcers and gastric mucosal histamine, and significantly increased gastric glutathione level, mucin content and free acidity107,108-110; they also protected against I/R-induced gastric oxidative stress and lesions111, and the oil was reported to decrease pro-inflammatory cytokines, lactate dehydrogenase, TG, and TC in trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats112.

Hepatoprotective effects

Liver is the main organ for the detoxification of harmful substances that enter the body, but it is also the target of various hepatotoxic agents, such as prescription drugs and environmental toxins. Black seeds supplemented diet protected against lead acetate-induced113, and isoniazid-induced hepatotoxicity114,115, and fixed oil and VO protected against ethanol-induced oxidative stress and liver damage116,117. Oral administration of water suspension and extract of the seeds was also protective against carbon tetrachloride (CCl4)-induced hepatotoxicity118,119, so were both the fixed oil120, and VO120-122. VO completely protected against d-galactosamine hepatotoxicity123, alleviated CCl4-induced suppression of CYP2B, CYP3A2, CYP2C11 and CYP1A2124, protected liver against the effects of hypervitaminosis A125, against I/R injury126, and decreased lipid peroxidation, liver enzymes and increased antioxidant enzyme levels127,128. Overall, the seeds and oils were significantly protective against various hepatotoxic agents129. TQ was the only constituent of VO that could efficiently protect against chemically-induced hepatic damage130.

Nephroprotective effects

Powdered seeds administration significantly lowered serum creatinine with no effect on kidney architecture in healthy rats131, and protected kidneys against I/R injury132-135. Treatment with the oil significantly ameliorated gentamicin nephrotoxicity in rats136-138, sodium nitrite nephrotoxicity139, diabetic nephropathy140, attenuated bromobenzene-induced hepatorenal injury141, significantly normalised physiological parameters and prevented acetaminophen-induced structural changes in kidneys142, protected against I/R injury of kidneys143,144, and attenuated the cyclosporine-induced oxidative stress and nephrotoxicity in rats145. TQ also protected against acute renal toxicity of gentamicin146, doxorubicin-induced nephropathy147, cadmium-induced oxidative stress and nephrotoxicity148, and ameliorated formation of ethylene glycol-induced renal calculi in rats149.

Reproductive effects

The diet of male mice supplemented with seeds significantly increased the testosterone level and ameliorated the deleterious effects of heat on spermatogenesis and antioxidant status150. Male rats treated with oil also had significantly higher percentage of motile normal and live sperm151, improved semen formation152, and increased sperm viability153,154. Conversely, VO administration significantly decreased serum testosterone levels in male mice155.
quality and moderated chlorpyrifos-induced reproductive toxicity\textsuperscript{152}. Low-dose seeds exerted prominent oestrogenic like effects on reproductive organs of ovariectomised rats\textsuperscript{153}, and AE significantly increased milk production in rats\textsuperscript{154}. However, the VO inhibited the spontaneous and oxytocin induced contractions of rat and guinea pig uterine isolated smooth muscle\textsuperscript{155}.

**Clinical studies**

The results of clinical studies are presented in Table 2.

**Hyperglycaemia and dyslipidaemia**

Supplementation of 94 Saudi patients of either sex with uncontrolled type 2 diabetes and HbA1c > 7%, with 1, 2, and 3 g/day of black seeds powder, an optimal dose of 2 g/day as an adjunct to oral antidiabetic drugs for twelve weeks, had significant reduction in TC, LDL-C, TG, and significant increase in HDL-C/LDL-C ratio\textsuperscript{156}, significant reduction in FBG, HbA1c, and insulin resistance without significantly affecting body weight\textsuperscript{157}; and continuing the treatment (2 g/day) for one year also significantly reduced insulin resistance, improved antioxidant defense capacity\textsuperscript{158}, had a significant reduction in SBP, diastolic blood pressure (DBP), MAP and HR\textsuperscript{159}, and 30 patients significantly decreased HbA1c, improved LV systolic function, and were protected from diastolic dysfunction compared to 30 placebo-treated patients\textsuperscript{160}. In a randomised controlled trial (RCT), hypercholesterolaemic Iranian patients treated with 2 g of black seeds powder daily for four weeks had a significant decrease in TC, LDL-C and highly significant decrease in TG, but no significant effect on FBG\textsuperscript{161}, and administration of powdered seeds in a dose of 3 g/day along with garlic capsules for eight weeks to 30 healthy postmenopausal Emirati women significantly improved blood oxidants and antioxidants balance\textsuperscript{162}, whereas 19 postmenopausal hyperlipidaemic Malaysian women and 15 with metabolic syndrome, treated with powdered seeds 1 g daily after breakfast for two months showed no significant reduction in body weight but a significant fall in FBG, TC, LDL-C, and TG, and increased HDL-C\textsuperscript{163,164}. In a double-blind, crossover RCT, consumption of bread containing black seeds for two months by 27 Iranian patients of either sex with metabolic syndrome did not have any significant effects on TC, LDL-C, TG, and HDL\textsuperscript{165}. However, supplementation of powdered seeds (2 g daily) to 10 young sedentary overweight Iranian women coupled with aerobic exercise for eight weeks synergistically lowered TC, LDL-C, TG, and body mass index (BMI), and increased HDL-C, compared to 10 women who were assigned to aerobic training alone\textsuperscript{166}. Sixty-nine perimenopausal and menopausal Malaysian women treated with 800 mg of seed powder twice daily for twelve weeks showed significant improvement in the prevalence and severity of menopausal symptoms and LDL-C, but no significant changes in TC, TG and HDL-C\textsuperscript{167}. In a double-blind RCT, obese premenopausal Iranian women with BMI between 30 and 35 kg m\textsuperscript{-2} treated with seed oil (1 g before each meal) and low calorie-diet, or placebo for eight weeks, had significant reduction in body weight and waist circumference, and significant decline in LDL-C and TG levels, compared to placebo\textsuperscript{168}, increased superoxide dismutase levels, but no significant changes in lipid peroxidation, glutathione peroxidase, and total antioxidant capacity compared to the placebo group\textsuperscript{169}. A meta-analysis of 17 RCTs concluded that supplementation with black seeds resulted in an average reduction of 15.6 mg/dL of TC, 14.1 mg/dL of LDL-C, and 20.6 mg/dL of TG. Seed oil lowered TC and LDL-C better than the seed powder; increase in HDL-C levels was, however, observed only with seed powder supplementation\textsuperscript{170}. Another meta-analysis of seven RCTs in type 2 diabetics found that black seeds supplementation produced an average reduction of more than 17 mg/dl in FBG, and 22 mg/dl in TC and LDL-C, with no significant effects on TG and HDL-C\textsuperscript{171}.

**Cardiovascular**

In a double-blind RCT, healthy Iranian volunteers, aged 34 to 63 years, 2.5 mL of black seed oil twice daily for eight weeks significantly lowered both SBP and DBP from baseline and compared to the placebo group\textsuperscript{172}, and a seed extract for two months significantly reduced both SBP and DBP, and the TC and LDL-C in mildly hypertensive patients\textsuperscript{173}. Meta-analysis of eleven RCTs involving 860 hypertensive or normotensive subjects reported a mean decrease of 7.66 mmHg in SBP and 4.89 mmHg in DBP after a mean treatment duration of 8.3 weeks with black seeds\textsuperscript{174}. However, treatment of 30–45 years old Indonesian men with central obesity with 750 mg seeds twice daily for three months, highly significantly reduced body weight and waist circumference, but an insignificant reduction in SBP, DBP, and serum free testosterone, compared to placebo-treated group\textsuperscript{175}; similarly, powdered seeds treatment of Iranian patients with Hashimoto’s thyroiditis for eight weeks, significantly reduced body weight, BMI, and serum concentrations of thyroid stimulating hormone (TSH), and VEGF\textsuperscript{176}. Administration of seeds (5 g daily) for 3–9 consecutive months to children (2–18 years) with brain tumours undergoing chemotherapy, reduced febrile neutropenia episodes to 2.2%, compared to 19.3% in control patients\textsuperscript{177}.

**Inflammation**

In a placebo-controlled study, the number of swollen joints and the duration of morning stiffness in 40 Egyptian female patients with rheumatoid arthritis improved after oral treatment with seed oil capsules 450 mg twice daily for a month\textsuperscript{178}. Similar results were reported from a double-blind RCT in 42 Iranian female patients with rheumatoid arthritis treated with the oil or placebo for eight weeks, that also reported reduced oxidative stress\textsuperscript{179}. However, administration of seed powder 2 g/day in divided doses to 55 Iranian patients with knee osteoarthritis did not significantly differ from
### Table 2: Brief characteristics of clinical studies on black seeds (Nigella sativa L.)

<table>
<thead>
<tr>
<th>Study year</th>
<th># of patients</th>
<th>Form of use and dose</th>
<th>Type of study and targeted subjects</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>860</td>
<td>Powdered seeds</td>
<td>Meta-analysis of RCTs, hypertensive and normotensive subjects</td>
<td>Short-term treatment significantly reduced SBP and DBP.</td>
</tr>
<tr>
<td>2016</td>
<td>42</td>
<td>Powdered seeds</td>
<td>Randomized controlled, comparator study in patients with metabolic syndrome</td>
<td>Significant reduction in TG, TC, LDL-C, HDL-C and increased in HDL-C.</td>
</tr>
<tr>
<td>2016</td>
<td>52</td>
<td>Powdered seeds</td>
<td>Randomized, double-blind, controlled trial in patients with metabolic syndrome</td>
<td>Significant reduction in FBG, HbA1C and improvement in systolic function.</td>
</tr>
<tr>
<td>2016</td>
<td>42</td>
<td>N.S. oil, 1000 mg/day for 8 weeks</td>
<td>Randomized controlled, placebo-controlled study in patients with metabolic syndrome</td>
<td>Significant reduction in body weight and waist circumference.</td>
</tr>
<tr>
<td>2016</td>
<td>52</td>
<td>Topical application of N.S. oil to breasts, twice daily for 2 months</td>
<td>Randomized, double-blind, cross-over clinical study in patients with cyclic mastalgia</td>
<td>Significant improvement in pain scores.</td>
</tr>
<tr>
<td>2016</td>
<td>51</td>
<td>Seeds supplemented bread for 2 months or placebo</td>
<td>Randomized, placebo-controlled, nonrandomised study in patients with metabolic syndrome</td>
<td>No significant effects on TG, TC, LDL-C, HDL-C, APO-A, APO-B and high-sensitivity CRP.</td>
</tr>
<tr>
<td>2016</td>
<td>60</td>
<td>Powdered seeds</td>
<td>Randomised, placebo-controlled, nonrandomised study in patients with metabolic syndrome</td>
<td>Significant reduction in HbA1c.</td>
</tr>
<tr>
<td>2015</td>
<td>114</td>
<td>N.S. oil 2.5 ml twice daily or placebo</td>
<td>Randomised, placebo-controlled, nonrandomised study in patients with metabolic syndrome</td>
<td>Significant reduction in FBG, HbA1C, and improvement in systolic function.</td>
</tr>
<tr>
<td>2015</td>
<td>50</td>
<td>N.S. oil 3 g/day with a low-calorie diet for 8 weeks or placebo</td>
<td>Randomised, placebo-controlled, nonrandomised study in patients with metabolic syndrome</td>
<td>No significant effects on TG, TC, LDL-C, HDL-C, APO-A, APO-B and high-sensitivity CRP.</td>
</tr>
<tr>
<td>2015</td>
<td>90</td>
<td>N.S. oil 3 g/day with a low-calorie diet for 8 weeks or placebo</td>
<td>Randomised, placebo-controlled, nonrandomised study in patients with metabolic syndrome</td>
<td>No significant effects on TG, TC, LDL-C, HDL-C, APO-A, APO-B and high-sensitivity CRP.</td>
</tr>
<tr>
<td>2015</td>
<td>70</td>
<td>Honey-based formulation of N.S. 1 g/day</td>
<td>Randomised, placebo-controlled, nonrandomised study in patients with metabolic syndrome</td>
<td>Significant reduction in body weight and waist circumference.</td>
</tr>
<tr>
<td>2015</td>
<td>37</td>
<td>Powdered seeds</td>
<td>Randomised, placebo-controlled, nonrandomised study in patients with metabolic syndrome</td>
<td>Significant reduction in SBP and DBP.</td>
</tr>
<tr>
<td>2015</td>
<td>30</td>
<td>Powdered seeds</td>
<td>Randomised, placebo-controlled, nonrandomised study in patients with metabolic syndrome</td>
<td>Significant reduction in SBP and DBP.</td>
</tr>
<tr>
<td>2015</td>
<td>69</td>
<td>Powdered seeds</td>
<td>Randomised, placebo-controlled, nonrandomised study in patients with metabolic syndrome</td>
<td>Significant reduction in SBP and DBP.</td>
</tr>
<tr>
<td>2014</td>
<td>20</td>
<td>Powdered seeds</td>
<td>Randomised, placebo-controlled, nonrandomised study in patients with metabolic syndrome</td>
<td>Significant reduction in SBP and DBP.</td>
</tr>
<tr>
<td>2014</td>
<td>48</td>
<td>Powdered seeds</td>
<td>Randomised, placebo-controlled, nonrandomised study in patients with metabolic syndrome</td>
<td>Significant reduction in SBP and DBP.</td>
</tr>
<tr>
<td>2014</td>
<td>42</td>
<td>Powdered seeds</td>
<td>Randomised, placebo-controlled, nonrandomised study in patients with metabolic syndrome</td>
<td>Significant reduction in SBP and DBP.</td>
</tr>
<tr>
<td>2013</td>
<td>70</td>
<td>Powdered seeds</td>
<td>Randomised, placebo-controlled, nonrandomised study in patients with metabolic syndrome</td>
<td>Significant reduction in SBP and DBP.</td>
</tr>
<tr>
<td>Study year</td>
<td># of patients</td>
<td>Form of use and dose</td>
<td>Type of study and targeted subjects</td>
<td>Results</td>
</tr>
<tr>
<td>------------</td>
<td>---------------</td>
<td>----------------------</td>
<td>-----------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>2013</td>
<td>52</td>
<td>N.S. oil, Betamethasone or Eucerin Cream applied twice daily for 4 weeks</td>
<td>Double-blind, randomised, comparative study in patients with hand eczema</td>
<td>Both N.S. and Betamethasone ointments significantly and rapidly improved eczema symptoms than Eucerin</td>
</tr>
<tr>
<td>2013</td>
<td>1</td>
<td>Seeds concoction (10 ml twice daily) for six months</td>
<td>An adult HIV patient</td>
<td>Sero-negative on 187th day on N.S. therapy and remained negative for 24 months without further therapy</td>
</tr>
<tr>
<td>2013</td>
<td>30</td>
<td>Seeds (450 mg thrice daily) for 3 months</td>
<td>Patients with hepatitis C virus (HCV) infection not eligible for interferon (IFN)-α therapy</td>
<td>Significant improvement in HCV viral load, RBC and platelet counts</td>
</tr>
<tr>
<td>2012</td>
<td>94</td>
<td>Powdered seeds 1, 2 and 3 g/day for 12 weeks</td>
<td>Uncontrolled, nonrandomised study in type 2 diabetes patients</td>
<td>Significant improvement in HCV viral load, alpha Fetoprotein, and liver function tests</td>
</tr>
<tr>
<td>2012</td>
<td>88</td>
<td>Powdered seeds 2 g/day for 4 weeks</td>
<td>Randomised, placebo-controlled study in hypercholesterolaemic patients</td>
<td>Significant decline in TC, TG, and LDL-c, but no effect on FBG and HDL-C</td>
</tr>
<tr>
<td>2012</td>
<td>40</td>
<td>Oil, 500 mg/twice daily for one month</td>
<td>Placebo-controlled rheumatoid arthritis female subjects</td>
<td>Joints swelling and morning stiffness significantly improved</td>
</tr>
<tr>
<td>2011</td>
<td>66</td>
<td>Oil or placebo for 30 days</td>
<td>Double-blinded study of patients with allergic rhinitis</td>
<td>N.S. oil reduced symptoms of allergic rhinitis</td>
</tr>
<tr>
<td>2010</td>
<td>39</td>
<td>Powdered seeds 750 mg/twice daily for 3 months</td>
<td>Controlled, nonrandomised study in men with central obesity</td>
<td>Significant reduction in body weight and waist circumference</td>
</tr>
<tr>
<td>2010</td>
<td>94</td>
<td>Powdered seeds 1, 2 and 3 g/day for 3 months</td>
<td>Uncontrolled, randomised study in uncontrolled type 2 diabetes patients</td>
<td>Significant reduction in FBG, 2 hours postprandial blood glucose (2hPG), HbA1c, and insulin resistance</td>
</tr>
<tr>
<td>2010</td>
<td>88</td>
<td>Powdered seeds 1, 2 or 3 g/day + Omeprazole for 4 weeks or Triple Therapy</td>
<td>Comparative, open-label, randomised study in patients with dyspepsia and positive H. pylori</td>
<td>Significant improvement in dyspeptic symptoms by N.S. comparable to conventional therapy, but H. pylori control better by triple therapy</td>
</tr>
<tr>
<td>2010</td>
<td>15</td>
<td>Seeds boiled extract 50 or 100 mg/kg</td>
<td>Comparative bronchodilatory effects of N.S. and theophylline in asthmatic patients</td>
<td>Potent anti-asthmatic effect of N.S. extract but weaker than theophylline</td>
</tr>
<tr>
<td>2010</td>
<td>12 Allergic rhinitis and 8 healthy subjects</td>
<td>Powdered seeds (2 g/day) for 30 days, as adjunct to immunotherapy</td>
<td>Controlled, parallel study on allergic rhinitis patients with sensitivity to house dust mites, and healthy subjects</td>
<td>Significant increase in CD8 Counts and increased phagocytic and intracellular killing activities of PMNs</td>
</tr>
<tr>
<td>2008</td>
<td>-</td>
<td>Seed extract 100 or 200 mg or Placebo twice daily for 8 weeks</td>
<td>Double-blinded RCT in mildly hypertensive patients</td>
<td>Dose-dependent significant reduction in SBP and DBP, and TC and LDL-C</td>
</tr>
<tr>
<td>2007</td>
<td>29</td>
<td>Seeds boiled extract 15 mL/kg of 0.1 g/day for 3 months</td>
<td>Randomised, placebo-controlled study in asthmatic adult patients</td>
<td>Significant improvement in all asthma symptoms, (frequency, symptoms/week, chest wheezing) and PFT</td>
</tr>
<tr>
<td>2007</td>
<td>20</td>
<td>Aqueous extract 40 mg/kg/d8h for 4 weeks as adjunct therapy</td>
<td>Double-blinded crossover clinical trial of children (13 months to 13 years old) with refractory epilepsy</td>
<td>Significantly decreased mean frequency of seizures</td>
</tr>
<tr>
<td>2003</td>
<td>152</td>
<td>N.S. oil capsule 40 to 80 mg/kg/day</td>
<td>Uncontrolled, German adult patients with allergic diseases</td>
<td>Subjective symptoms improved</td>
</tr>
</tbody>
</table>
55 placebo-treated patient in a double-blinded RCT\(^{180}\). In a triple-blind, active RCT, topical application of seed oil also provided significant relief from mastalgia associated with menstrual cycle, comparable to topical diclofenac use\(^{181}\). Compared to fish oil, application of VO to vitiligo patches for six months significantly improved patches on upper extremities, trunk, head, and neck\(^{182}\), and VO application twice a day significantly improved hand eczema, similar to the application of betamethasone\(^{183}\).

**GIT**

Adult Saudi patients suffering from non-ulcer dyspeptic symptoms and positive for *H. pylori* infection, comparatively treated either with conventional triple antibiotic therapy or with seeds and omeprazole equally improved dyspepsia symptoms but did not show better anti *H. pylori* effect than the triple antibiotic therapy\(^{184}\). However, when Iranian patients with functional dyspepsia were treated with a daily dose of seed oil (5 ml) mixed with honey for eight weeks in a double-blind RCT, it significantly improved dyspeptic symptoms and significantly lowered *H. pylori* infection compared to placebo group\(^{185}\).

**Allergy and asthma**

Boiled seed extract to 15 asthmatic Iranian patients as an adjunct to asthma therapy further improved asthma symptoms and decreased the usage of rescue inhaler, oral beta-agonists, oral corticosteroid, oral theophylline and the corticosteroid inhaler by the end of three months study period\(^{186}\). The onset time of brochodilatory effect was 30 min, and lasted for 150 min, similar to but less than the effect of theophylline\(^{187}\). A supplementary dose of seeds (2 g/day) to partly controlled 26 Saudi asthma patients for 12 weeks improved significantly both the peak expiratory flow (PEF) and forced expiratory volume in 1 second (FEV-1) in a single-blind RCT\(^{188}\), and the seed oil (500 mg twice daily) supplementation to 40 Saudi asthmatics for four weeks, significantly improved mean Asthma Control Test score, significantly reduced blood eosinophils, and improved FEV-1 in a double-blind RCT\(^{189}\). Oral VO treatment in a dose of 40 to 80 mg/kg/day improved subjective feeling score over the course of the treatment, in a total of 152 German patients with allergic diseases, such as allergic rhinitis, bronchial asthma, and atopic eczema\(^{190}\). In a double-blind, prospective study, 66 Iranian patients with allergic rhinitis treated with VO or placebo for 30 days, had improvement in their nasal mucosal congestion, nasal itching, runny nose, sneezing attacks, turbinate hypertrophy, and mucosal pallor in the treatment group\(^{191}\). Similarly, 12 Turkish patients sensitive to house dust mites with allergic rhinitis receiving immunotherapy supplemented with seed (2 g/day orally) for 30 days showed a significant increase in CD8 counts, and significantly increased phagocytic and intracellular killing activities of polymorphonuclear leukocytes compared to 12 patients receiving only specific immunotherapy\(^{192}\). Also, in a prospective, crossover RCT of 42 Turkish geriatric patients with nasal dryness and related symptoms, two weeks’ topical application of VO significantly improved nasal dryness, obstruction and crusting\(^{193}\).

**HIV and HCV**

In a dramatic case of a 46-year-old Nigerian sero-positive HIV patient with multiple papular pruritic lesions, 10 ml concoction of seeds twice daily was allegedly administered by a herbalist that resulted in clearance of his pruritic lesions by 20th day and became seronegative after six months treatment, and remained so for twenty-four months follow up without further treatment\(^{194}\). The seed oil (450 mg tid) administered to 30 Egyptian patients with positive hepatitis C virus (HCV) infection with chronic liver disease or liver cirrhosis, not eligible for interferon (IFN)-\(\alpha\) therapy, significantly improved the HCV viral load, improved clinical symptoms, oxidative stress, and reduced blood glucose in those with diabetes\(^{195}\).

**Miscellaneous**

Oral administration of 500 mg powdered seeds twice daily to 20 healthy elderly Bangladeshi volunteers for nine weeks significantly enhanced memory, attention and cognition\(^{196}\), and stabilised mood, decreased anxiety and modulated cognition in 20 healthy adolescent male volunteers compared to equal numbers of placebo-treated individuals\(^{197}\). In a double-blinded crossover clinical trial, addition of aqueous black seed extract (40 mg/kg thrice daily) for four weeks as an adjunct to anticonvulsant therapy in 20 children aged 13 months to 13 years old with refractory epilepsy, significantly decreased the frequency of seizures\(^{198}\). In a double-blind RCT, 34 Iranian infertile men with abnormal semen quality treated with 2.5 ml of seed oil twice daily for two months significantly improved sperm morphology, count, motility and semen volume, compared to 34 men treated with placebo\(^{199}\).

**CYP450 and drug–drug interactions**

Black seeds aqueous extract significantly inhibited *in vitro* CYP2D6 and CYP3A4 in human liver microsomes and in healthy human volunteers\(^{200}\), and seven days’ administration of seeds to rats also significantly inhibited the mRNA and protein expression levels of CYP2C11\(^{201}\). Co-administration of black seeds significantly reduced phenytoin elimination in dogs\(^{202}\), reduced AUC, Cmax and half-life of sildenafil in beagle dogs\(^{203}\), significantly decreased the Cmax and AUC of cyclosporine\(^{204}\), but did not affect the pharmacokinetics of carbamazepine in rabbits\(^{205}\).

**Human adverse effects/toxicity**

Although not many cases of adverse effects or toxicity are reported, a few deserve to be mentioned here, which resolved after discontinuing the use of oil without any sequelae. Use of topical preparations containing black seed oil caused allergic contact dermatitis in German patients\(^{206,207}\), and a 53-year-old French woman developed systemic erythematous plaques with vesicles and
bullous lesions after ingesting and topically using black seed oil for two weeks.\textsuperscript{200}

**Animal toxicity**

Black seeds supplemented the diet of Sprague-Dawley rats up to a dose of 1 g/kg for four weeks did not cause any signs of liver dysfunction.\textsuperscript{201} However, oral administration of AE to male Sprague-Dawley rats for 14 consecutive days was reported to significantly increase serum aminotransferase concentrations with no histopathological changes in hepatocytes, but an oral dose of 6 g/kg/day for 14 consecutive days to mice caused some degenerative changes in hepatocytes, LD50 (i.p.) of the AE is reported to be 4.23 g/kg. Oral and i.p. LD50s of the fixed oil in mice were reported to be 28.8 ml/kg and 2.06 ml/kg, respectively; the oral dose of 2 ml/kg fixed oil for 12 weeks to rats did not cause any histopathological changes in heart, liver, kidneys and pancreas, and fixed oil orally to mice in a dose of 10 ml/kg for 15 days was also nonlethal.\textsuperscript{211}

**Discussion**

From the experimental and clinical studies, it is apparent that black seeds exert a broad spectrum of pharmacological and clinical effects that could directly or indirectly affect a disease outcome or overall health status. Blood glucose and lipid profile appear to be the most significantly affected parameters. An improvement in lipid profile, blood glucose and/or blood pressure is most significantly affected parameters. An improvement in lipid profile, blood glucose and/or blood pressure is potentially likely to help in controlling the most common diseases of our time. However, the observations of the clinical studies indicate that the optimal daily dose of black seeds is 2 g/day and use of a lesser dose does not offer the full benefits; the dose of VO or extract should correspond to the optimal dose of the seeds. Secondly, the duration of most clinical studies and the number of patients involved are limited, and standard control groups are sometimes lacking. Also, there is a paucity of follow-up clinical studies to reproduce the clinical outcomes. Studies in more diverse populations, of longer duration involving significantly higher number of patients would be helpful in determining the reproducibility and the lasting impact of beneficial effects. Sometimes, a lower dose used over a longer period of time may offer the same benefits as a higher dose used for shorter periods. Moreover, the chemical composition of seeds used in clinical studies were either not determined or not reported. As has been mentioned earlier, the seeds vary remarkably in their chemical contents, both qualitatively and quantitatively, which should affect the clinical outcomes, if one relies on the constituents–effects relationship. Until more detailed randomised, controlled clinical trials are conducted, the jury will be out for a definitive answer about the potential usefulness of black seeds, but the trend points to positive health benefits.

Inhibition of CYP2D6 and CYP3A4 by black seeds, the two enzymes most commonly involved in the metabolism of prescription drugs, is likely to increase the possibility of a drug–drug interaction, resulting in adverse effects and toxicity of other prescription drugs metabolised by these enzymes. The significant decrease in the Cmax and AUC of cyclosporine, if true in humans, could negatively affect the intended immunosuppression in patients where black seeds are used concurrently with ciclosporin.

**Declaration of interest**

The author has no conflicts of interest to report.

**References**


© NHAA 2018


Zedlitz S, Kaufmann R, Boehncke WH. Allergic contact dermatitis from black cumin (Nigella sativa) oil-containing ointment. Contact Dermatitis 2002;46(3):188.


重大澳大利亚认证有机
和野采

PPC为医疗专业人员提供了一种选择，要么选择传统上制作的草药提取物；要么选择新鲜的草药浸剂和新鲜的植物材料，这些材料都在收获后几小时内被加工。 

The Pharmaceutical Plant Company具有25年制造和分发传统草药提取物、新鲜草药浸剂和注册药品的经验。

有关我们草药提取物或草药药物的更多信息，请访问www.ppcherbs.com.au或联系我们sales@ppcherbs.com.au。
Comparative effects of mistletoe extracts in combination with 5-Fluorouracil on viability of IEC-6 and Caco-2 intestinal epithelial cells

Zahra Lotfollahi Hons, Suzanne Mashtoub PhD, Gordon S Howarth PhD, Lauren C Chartier Hons, Ljubov Simson PhD, Ker Y Cheah PhD and Susan EP Bastian PhD

Discipline of Physiology, Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia
Gastroenterology Department, Women’s and Children’s Hospital, North Adelaide, SA, Australia
School of Medicine, The University of Western Australia; Fiona Stanley Hospital, Murdoch, WA, Australia
School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy Campus, SA, Australia
Faculty of Applied Sciences, University of Canberra, Canberra, ACT, Australia
School of Agriculture, Food and Wine, The University of Adelaide, Adelaide, SA, Australia

Abstract

**Background:** Colorectal cancer is the second most common cancer in Western countries. Mistletoe extract has been used for decades as a complementary cancer therapy in Europe to improve patient general condition, vitality, pain and appetite.

**Aim:** To examine the effect of mistletoe extracts (Quercus, Fraxini and Mali) on the viability of colon cancer and normal intestinal cells.

**Materials/methods:** Cell viability of IEC-6 (non-transformed) and Caco-2 (colon cancer) cells was determined by MTT assay for mistletoe extracts (Quercus, Fraxini and Mali; aqueous; 1–100 µg/mL) alone and in combination with 5-Fluorouracil (5-FU). p < 0.05 was considered significant.

**Results:** IC50 values on Caco-2 cells for Fraxini, Mali and Quercus were 42.7, 65.5 and 84.4 µg/mL, respectively. IC50 values for Fraxini, Mali and Quercus on IEC-6 cells were 71.74, 65.52 and 84.39 µg/mL, respectively. Fraxini (50 µg/mL), when combined with 5-FU (5 µM), significantly increased the potency of 5-FU on IEC-6 cells compared to Fraxini (50 µg/mL) alone (p<0.05). Quercus was less effective than Fraxini at reducing Caco-2 cell viability. However, effects on IEC-6 cells were also less pronounced. Mali was the least effective extract on both cell lines.

**Conclusion:** Fraxini was the most potent mistletoe extract at decreasing colon cancer cell viability.

**Keywords:** Cell culture, chemotherapy, gastrointestinal diseases, mistletoe extracts.

Introduction

Colorectal cancer is the second most prevalent cause of cancer-related death in Western countries. Chemotherapy, particularly 5-Fluorouracil (5-FU), is used for the most advanced stages (III and IV) of colon cancer. Unfortunately, the indiscriminate mode of action of 5-FU not only targets cancer cells but also kills the rapidly proliferating cells in human body such as cells lining the gastrointestinal tract (enterocytes). Enteroocyte damage results in severe side effects, including mucositis. Mucositis is characterised by inflammation and ulceration of mucosal tissue in the gastrointestinal tract. The severity of 5-FU-related side-effects can result in the cessation of chemotherapy. Therefore, new therapeutic agents with specific toxicity to colon cancer cells are desirable, without exacerbating the undesirable impact of 5-FU on the normal healthy intestine cells.

Mistletoe is a semi-parasitic plant, which grows on several types of tree such as oak (Quercus), pine (Pinus), apple (Mali) and ash (Fraxini). Mistletoe extract (ME; Viscum album L.) was introduced in 1920 by Rudolf Steiner as an anticancer substance. Aqueous MEs have been used for several decades as an adjunctive complementary cancer therapy in Europe. A recent review concluded that mistletoe therapy resulted in long-term disease stability, improvements in patient general condition, vitality, strength, pain, sleep, and appetite. Furthermore, chemotherapy was better tolerated and patients displayed improved emotional and mental condition following mistletoe therapy. The therapeutic efficacy is attributed primarily to the mistletoe lectins. Other cytotoxic components of ME include viscoxin and alkaloids. The composition of ME varies depending on factors such as the host tree, the extraction technique and the manufacturing process.
Mistletoe lectin (ML) is a heterodimeric glycoprotein which belongs to the class of ribosome-inactivating protein type II. ML comprises a toxic chain A (N-glycosidase enzyme) and chain B (galactoside-recognising lectin). It has been proposed that ML induces tumor death as chain B of ML binds to the cell surface and then chain A inhibits protein synthesis. The glycoprotein expression on the membrane of tumor cells differs from normal cells and has a higher binding affinity for mistletoe lectins. Therefore, ME toxicity to normal cells is less pronounced indicating selective toxicity to tumor cells. However, to date the comparative effects of MEs on normal and transformed intestinal epithelial cells have not been investigated.

In the current study, we examined MEs from three different tree species (ash, oak and apple) for their toxicity. MEs were extracted from ABNOBA Pty Ltd (Germany). The extracts were kindly provided by A/Prof Ljubov Simson. These samples were initially obtained in physiological saline were mixed with 5-FU and administered to IEC-6 and Caco-2 cells with the DMEM, respectively, the DMEM was replaced with 100 µL of each ME (1–100 µg/mL) followed by 48 hrs addition of MTT reagent and reading at 570 nm. For the experiments, which examined the effect of ME combined with 5-FU on cell viability, DMEM was replaced with 90 µL of each ME mixed with 10 µL of 5-FU.

Statistical analysis
All data are expressed as mean ± SEM. Statistical analyses were performed using XLSTAT Version 2012.6.03 (Addinsoft) and GraphPad Prism 6. The data for IC50 calculation and percentage of cell viability were analysed using one-way ANOVA and two-way ANOVA respectively with a Tukey’s post hoc test. P < 0.05 was considered statistically significant.

Results
IC50 values of MEs on IEC-6 and Caco-2 cells
The IC50 of Quercus on IEC-6 cells was significantly higher than on Caco-2 cells (84.39 and 64.54 µg/mL respectively; p < 0.05; Figure 1). Similarly, the IC50 of Fraxini was significantly higher on IEC-6 cells compared to Caco-2 cells (71.74 and 42.66 µg/mL respectively; p < 0.01; Figure 1). However, the IC50 for Mali was significantly lower when administered to IEC-6 cells compared to Caco-2 cells (65.52 and 86.75 µg/mL respectively; p < 0.05).

Effects of Quercus combined with 5-FU on viability of IEC-6 and Caco-2 cells
Efficacy of 5-FU was confirmed as the viability of 5-FU-treated cells decreased significantly by 30% for IEC-6 cells (p < 0.05; Figures 2A, 3A and 4A) and 50% for Caco-2 cells (p < 0.05; Figures 2B, 3B and 4B). Quercus (50µg/mL and 100 µg/mL; 10 µg/mL, 50 µg/mL and 100µg/mL, respectively) significantly decreased cell viability of IEC-6 and Caco-2 cells compared to cell controls (p < 0.05; Figures 2A and 2B). In IEC-6 cells, the combination of 5-FU (5 µM) with 100 µg/mL of Quercus increased the potency of 5-FU on IEC-6 cells (p < 0.05; Figure 2A). Importantly in the context of colon cancer treatment, Quercus (50 and 100 µg/mL) combined with 100 µM of 5-FU significantly decreased Caco-2 cell viability compared to 5-FU only treated cells (p < 0.05; Figure 2B).
Effects of *Fraxini* combined with 5-FU on viability of IEC-6 and Caco-2 cells

*Fraxini* (10, 50 and 100 µg/mL) significantly decreased viability of IEC-6 and Caco-2 cells compared to cell controls (p < 0.05; Figures 3a and 3b). In IEC-6 cells, *Fraxini* (50 µg/mL) combined with 5-FU (5 µM) significantly increased 5-FU potency compared to IEC-6 cells independently treated with either *Fraxini* or 5-FU (30%, p < 0.05, Figure 3A). After 48 hours, treatment of Caco-2 cells with the combination of *Fraxini* (50 and 100 µg/mL) and 5-FU (100 µM), resulted in significantly fewer viable cells (49% and 46% respectively) compared to cells exposed to 5-FU alone (71%, p < 0.05). Nonetheless, there was no significant difference between the viability of Caco-2 cells treated with *Fraxini* (50 and 100 µg/mL) compared to *Fraxini* in combination with 5-FU (100 µM; Figure 3B).

Effects of *Mali* combined with 5-FU on viability of IEC-6 and Caco-2 cells

*Mali* (50 µg/mL and 100 µg/mL) significantly decreased viability of IEC-6 and Caco-2 cells compared to cell controls (p < 0.05; Figures 4a and 4b). The combination of *Mali* (50 µg/mL and 100 µg/mL) with 5-FU (5 µM) significantly decreased IEC-6 cell viability compared to cells treated with 5-FU alone (p < 0.05, Figure 4A). Nevertheless, in IEC-6 cells, there was no significant difference in viability between *Mali* (50 µg/mL) and the combination of *Mali* and 5-FU (5 µM; Figure 4A). After 48hrs treatment of Caco-2 cells with *Mali* (50 and 100 µg/mL) and 5-FU (100 µM), cell viability was decreased (47% and 44% respectively) compared to cells exposed to 5-FU alone (77%). However, there was no significant difference between the viability of Caco-2 cells treated with *Mali* (50 and 100 µg/mL) compared to *Mali* in combination with 5-FU (100 µM; Figure 4B).

Figure 1: IC$_{50}$ values of *Quercus*, *Fraxini* and *Mali* for IEC-6 and Caco-2 cells. IC50s were calculated by MTT assay after 48hrs incubation. Data are expressed as mean (IC50) ± SEM of triplicate wells from two independent experiments. * indicates p < 0.05, ** indicates p < 0.01 compared to IEC-6 treated with same ME.

![Figure 2A](image)

![Figure 2B](image)

Figure 2: Effects of *Quercus* (1–100 µg/ml) and 5-FU (µM) in combination on viability of IEC-6 (A) and Caco-2 cells (B) after 48hrs. Data are expressed as mean (percentage of cell viability relative to serum free only treated cells) ± SEM of triplicate wells from 2–3 independent experiments. * indicates p < 0.05 compared to cell control (0 5-FU); # indicates p < 0.05 compared to cell control (5 and 100 µM 5-FU).

![Figure 3A](image)

![Figure 3B](image)

Figure 3: Effects of *Fraxini* (1–100 µg/ml) combined with 5-FU (µM) on viability of IEC-6 (A) and Caco-2 cells (B) after 48hrs. Data are expressed as mean (percentage of cell viability relative to serum free only treated cells) ± SEM of triplicate wells from 2–3 independent experiments. * indicates p < 0.05 compared to cell control (0 5-FU); # indicates p < 0.05 compared to cell control (5 and 100µM 5-FU); ^ indicates p < 0.05 between cells treated with 50 µg/ml of *Fraxini* and cells treated with *Fraxini* + 5µM of 5-FU.
Discussion

Despite advances in chemical-based medications, cancer patients are inclined to use naturally-sourced toxins due to adverse effects associated with chemotherapy and radiation\textsuperscript{20}. We investigated the effects of three different MEs (\textit{Quercus}, \textit{Fraxini} and \textit{Mali}), alone and in combination with 5-FU, on the viability of normal and transformed intestinal epithelial cells. \textit{Fraxini} was the most potent ME on Caco-2 cells; however, it significantly increased the potency of 5-FU chemotherapy on IEC-6 cells compared to \textit{Fraxini} alone (50 µg/mL). With the exception of \textit{Fraxini}, none of the MEs had a significant impact on IEC-6 cell viability when combined with 5-FU, compared to IEC-6 cells treated with 5-FU alone. Furthermore, \textit{Fraxini} was the only ME to increase 5-FU efficacy on Caco-2 cells above that of the same concentration of ME alone.

In the current study, \textit{Fraxini} had the greatest effect on Caco-2 cells compared to \textit{Mali} and \textit{Quercus}. This presumably reflected the highest concentration of lectin and viscotoxin in \textit{Fraxini} compared to \textit{Quercus} and \textit{Mali} (Table 1). In a study conducted by Ding and colleagues\textsuperscript{21}, the anti-proliferative activity of Fraxini was shown to be almost 10 and 6 times stronger than that of Iscador M and Iscador Q, respectively, in both Hep3B and HepG2 cells. Furthermore, \textit{Quercus} (with slightly higher lectin and viscotoxin levels; as shown in Table 1) was more toxic than \textit{Mali} when applied to Caco-2 cells.

<table>
<thead>
<tr>
<th>Mistletoe extract</th>
<th>Lectin (µg/mL)</th>
<th>Viscotoxin (µg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>\textit{Quercus}</td>
<td>6.37</td>
<td>50.33</td>
</tr>
<tr>
<td>\textit{Fraxini}</td>
<td>10.38</td>
<td>61.0</td>
</tr>
<tr>
<td>\textit{Mali}</td>
<td>6.02</td>
<td>45.95</td>
</tr>
</tbody>
</table>

Lectin and viscotoxin are believed to be the main biological active components of MEs contributing to their potency to cancer cells\textsuperscript{12,22}. These active components are reported to show anti-neoplastic effects by different mechanism of action including cell cycle arrest, induction of apoptosis, altering tumour angiogenesis and anti-inflammatory effects\textsuperscript{21-24}. However, the exact underlying mechanism of action of MEs is not clearly understood yet\textsuperscript{24}.

It is proposed that 5-FU and MEs induce cell death through distinct molecular mechanisms of action, which include inhibition of protein synthesis, activation of apoptotic cascades, such as p-53 independent apoptosis and inhibition of telomerase\textsuperscript{15,16,25}. Engdal (2009) demonstrated that MEs (Iscador M series II) inhibited the p-glycoprotein function of Caco-2 cells\textsuperscript{26}. On the other hand, 5-FU induces cell death by interfering with thymidylate synthase (TS) enzyme function and consequently inhibition of DNA synthesis\textsuperscript{27}. The MTT assay, employed in the current study, was limited in terms of distinguishing apoptosis from necrosis of cells treated with MEs. Future assays which measure direct DNA binding and determine cell apoptosis, such as \textsuperscript{3}H-thymidine and Edu-IT, respectively, are recommended.

Another interesting observation was the greater efficacy of \textit{Mali} on IEC-6 cells compared to Caco-2 cells. Previous \textit{in vitro} studies have mainly focused on the impact of MEs on tumour cell lines and not the normal human cell lines. Further experiments are necessary to investigate the factors influencing the higher potency of \textit{Mali} on normal intestine cells compared to colon cancer cells.

Apart from possessing the lowest IC\textsubscript{50}, \textit{Fraxini} (50 µg/mL combined with 5-FU) significantly potentiated 5-FU on IEC-6 cells compared to the same concentration of \textit{Fraxini} alone. The study by Cazacu and his colleagues (2003) showed that mistletoe therapy (Isorel) as an adjunct to 5-FU chemotherapy after surgery improved survival rate and also alleviated chemotherapy side-effects (digestive and/or hematological toxicity) of colon cancer patients\textsuperscript{16}.

In the current study, none of the MEs protected the normal intestinal cells from 5-FU toxicity. Similar results were obtained in a recent study done by Weissenstein and colleagues, as \textit{Viscum album} extraction did not inhibit chemotherapy-induced toxicity on 5 different cell lines\textsuperscript{22}. In clinical settings, internal factors, such as the...
immune system; a purported target of ME could have contributed to alleviation of chemotherapy side-effects after mistletoe therapy. Clearly these factors were absent in the present in-vitro study.

The most likely explanation for IC_{50} variations in Quercus, Fraxini and Mali is due to different magnitudes of toxic components in each. The aforementioned extracts originated from mistletoe bushes, which grow on different host trees and possess distinct compositions resulting in varying magnitudes of toxicity. As mentioned previously lectins can induce apoptosis through different pathways, some being more effective than others in specific cell lines, therefore resulting in different toxicity values for different cell lines.

Recently, Huber and colleagues conducted a maximum tolerable dose and safety investigation of intravenous mistletoe application. ME (200, 400, 700, 1200 or 2000mg) infusions were administered once weekly for 3 weeks in advanced cancer patients. A dose-limiting toxicity was not reached and no serious adverse events or suspected unexpected serious adverse events occurred as a result of mistletoe treatment. Furthermore, it was concluded that weekly infusions of ME at a starting dose of up to 2000mg is well-tolerated; however, at 2000mg dose, there is a minor risk of fever or allergic reaction. These results support the safety of mistletoe therapy in advanced cancer patients.

In summary, the current study indicated that all MEs significantly reduced viability of colon cancer cells (Caco-2), while not inhibiting 5-FU efficacy. However, all MEs differentially reduced IEC-6 cell viability. Importantly Quercus and Fraxini at lower doses exhibited greater toxicity to Caco-2 cells when compared to IEC-6 cells. These observations support previous studies describing ME as an ‘anticancer’ substance and warrant future studies in animal models of colon cancer. Interestingly, both Quercus and Fraxini potentiated the effects of 5-FU at higher doses. On the basis of the impact on IEC-6 and Caco-2 cells displayed in this study, Quercus would likely be the preferred candidate for further clinical development. MEs could represent a promising new adjunct to conventional chemotherapy regimens. Further studies are required to determine the optimal host tree species, optimal dosing regimen and the specific bioactive factors responsible.

Acknowledgements

This study was not funded or sponsored by any organisation, grants or any other resources. The full raw data are available and we are able to provide them in Excel format if requested by the journal. The authors have no other acknowledgements to disclose.

Declaration of interest

The authors have no conflicts of interest to report.

References


The naturopathic management of interstitial cystitis: A case study

Amy Taylor BHSc Naturopathy (final year student), BJourn^1, David Casteleijn MHSc Herbal Medicine^1^2^, and Sophia Gerontakos BHSc Naturopathy^1^2

^1^Endeavour College of Natural Health, Fortitude Valley Brisbane, QLD, Australia
^2^University of Technology Sydney, Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, Ultimo, NSW, Australia

Contact information
Amy Taylor, Endeavour College of Natural Health, Level 2, 269 Wickham St, Fortitude Valley, Brisbane, QLD 4006
Email amy.elyn@hotmail.com

Abstract
This case study describes the treatment of a middle-aged woman with symptoms of increased urgency and frequency of urination, and incomplete voiding, consistent with the diagnosis of interstitial cystitis (IC). Treatment was underpinned by holistic philosophy and incorporated the naturopathic principle, ‘treat the whole person’. Aggravating and sustaining factors, including chronic stress, nervous system dysregulation and inflammation, were identified and addressed using herbal medicine. The client reported alleviation of symptoms within two weeks of naturopathic treatment, as well as improvements of other characteristic symptoms, including sleep onset and quality, increased energy levels, resolution of restless legs, and decreased oedema in her feet and ankles. This case demonstrates the efficacy of naturopathy for treatment of symptoms associated with IC.

Keywords: Bladder, cystitis, interstitial cystitis, bladder pain, herbal medicine, naturopathy.

Introduction
Interstitial cystitis (IC) is a chronic inflammatory condition of the urinary tract with a common clinical presentation of urinary frequency, urgency and pain^1^2. Specific aetiology is unknown; however, there is some resemblance to urinary tract infection (UTI) but without presence of bacteria on urine cultures, and without response to antibiotic therapy^2^. IC is commonly associated with thinning of the bladder epithelium^3^, altered nerve signalling^2^ and increased apoptosis in urothelial cells^1^.

Associations between clinical characteristics of IC, and mood and personality traits were explored in a study in 2016^5^. Researchers found a significant correlation between the pain of IC and anxiety, depression and interpersonal problems, highlighting the potential benefits of a holistic naturopathic approach^5^. Persons with IC commonly present with associated anxiety and depression^5^, and report a decrease in quality of life and social wellbeing^5^. A holistic naturopathic approach includes consideration of all aspects that may impact on a person’s health and wellbeing, including pathology, physiology, as well as social and environmental factors.

In IC, the intensity of urinary symptoms such as urgency and pain are positively correlated with increased stress levels^7^, and sympathetic nervous system (SNS) dominance is a common underlying mechanism of pathogenesis^8^.

The following case study illustrates the whole person implications in the naturopathic management of a 54-year-old woman with symptoms associated with chronic IC. Alleviation of symptoms occurred following naturopathic treatment that incorporated methods to reduce chronic stress and inflammation.

Case description
The client, Rose*, is a 54-year-old female. Rose initially presented to the Wellnation student clinic in March 2018 with lower urinary tract symptoms (increased urinary urgency and frequency), and anxiety. She explained a need to urinate over 15 times per day and was experiencing incomplete voiding. There was no marked increase in urine volume (polyuria). She would pass urine only to feel a sense of urgency to urinate again less than five minutes later. Pain was present only if she had to ‘hold on’. These symptoms began 2–3 years prior and Rose could not identify any specific event occurring at that time. Since onset she had gradually reduced her water intake down to 1–2 glasses per day. She believed water was exacerbating her symptoms. Rose had not sought treatment from her general practitioner (GP) and noted she had experienced 1–2 incidents of cystitis over 20 years previously; however, she felt her current symptoms were different and unrelated.

Rose described delayed sleep onset (1–3 hours) due to ruminating thoughts, and disturbed sleep due to nocturia and restless legs. She woke un-refreshed approximately three times per week. Oedema was present in her ankles and lower legs.
Case study

Rose’s urinary tract symptoms were causing her increased anxiety and fear. She had modified some of her behaviours to accommodate her symptoms, avoiding places without easy access to a bathroom and always assessing the proximity of the nearest bathroom in new places. Her symptoms resulted in her feeling anxious and fearful about new situations. Rose described depressive-type symptoms of lethargy and feeling unmotivated and unenthusiastic. She was experiencing increased stress at work, and occasional constipation, which she associated with an increase in consecutive shifts. Rose had worked full time in a high-stress, 24/7, shift work environment for many years. Her diet consisted of processed and refined foods, and she described a habit of snacking on junk foods, which included sweets and potato chips. She said she frequently felt hungry between meals, particularly at work. She had identified that citrus, hot and spicy foods, and soft drink aggravated her symptoms. Rose was not taking any medications and had no reports from pathology testing. Her blood pressure was 125/85.

Case assessment

Rose’s work environment was noted as a cause of ongoing emotional and mental stress. Shift work and chronic stress may result in sympathetic nervous system (SNS) dominance, and occasional constipation, which in Rose’s case occurred specifically when she was at work. SNS dominance is defined as prolonged activation of the hypothalamus-pituitary-adrenal (HPA) axis and may result in a myriad of imbalances, including cortisol dysregulation. Shift work (specifically sleep loss and circadian disruption) is a physiological stressor, and may disturb cortisol regulation, and contribute to systemic inflammation.

Inflammatory cascades are self-perpetuating and in instances of chronic inflammation treatments aimed at breaking inflammatory feedback mechanisms may be relevant. There is a range of causative mechanisms of chronic inflammatory states; however, stress is noted as a common predisposing, exacerbating and sustaining factor.

Therefore, although Rose’s symptoms presented in the urinary tract, it was considered they were being exacerbated and sustained by her chronic stress and complicated by chronic systemic inflammation. Holistic naturopathic treatment incorporated these aspects as foundational aims of treatment, and utilised herbal medicine to reduce symptoms, provide stress relief and reduce inflammation, and improve Rose’s vitality and capacity to incorporate healthy behavioural and lifestyle changes.

Treatment

Herbal medicine was targeted to support healthy nervous system function, and to reduce inflammation. Behavioural recommendations included improved sleep hygiene and stress-reducing self-administered rituals (baths, aromatherapy, reading, breathing exercises, warm showers, and limited screen time before bed) aimed to promote relaxation. An increase in water consumption was also recommended, along with a decreased dietary intake of aggravating foods (spicy food, citrus and soft drinks).

The liquid herbal formula (Table 1) was created and Rose was instructed to take 7.5 mL twice daily in a small amount of water. The herbal tablet formula (Table 2) was prescribed at 4 tablets per day (2 x am, 2 x pm) with food.

Table 1: Liquid herbal formula

<table>
<thead>
<tr>
<th>Herbal mix 1 — liquid herbal formula</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Botanical</strong></td>
</tr>
<tr>
<td>Hypericum perforatum</td>
</tr>
<tr>
<td>Eleutherococcus senticosus</td>
</tr>
<tr>
<td>Scutellaria lateriflora</td>
</tr>
<tr>
<td>Schisandra chinensis</td>
</tr>
<tr>
<td>Crocus sativus</td>
</tr>
</tbody>
</table>

**Dose**

7.5 mL twice daily (am/pm) in a small amount of water

110 mL

Table 2: Tablet herbal formula

<table>
<thead>
<tr>
<th>Herbal mix 2 — tablet herbal formula (per tablet)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Botanical</strong></td>
</tr>
<tr>
<td>Boswellia serrata</td>
</tr>
<tr>
<td>Curcuma longa</td>
</tr>
<tr>
<td>Apium graveolens</td>
</tr>
<tr>
<td>Zingiber officinale</td>
</tr>
</tbody>
</table>

**Dose**

Two tablets twice daily (am/pm) with food

Treatment outcome

Rose reattended the clinic in March 2018, two weeks after her initial appointment. She reported increased energy levels and vitality and described a marked reduction in the frequency and urgency of her urinary symptoms. Sleep onset and quality had also improved, and she was no longer experiencing restless legs. The oedema in her feet and ankles had decreased. Rose felt
more energetic and capable of managing daily events and noted a significant benefit from the ‘unwinding’ routine before sleep.

Discussion

The unknown aetiology of IC can be a cause for confusion in identifying mechanistic treatment strategies. Numerous suggestions for the pathophysiologic mechanisms in IC have been proposed, including epithelial dysfunction, mast cell activation, and neurogenic inflammation. Although it remains unclear whether altered neural mechanisms and inflammation are causative, or resultant, they are an important consideration in treatment as neural upregulation plays a role in the chronic presentations of urgency and frequency in urinary tract symptoms. A naturopathic approach that incorporates multifactorial aspects of the individual case can facilitate consideration of the ‘whole person’ and simultaneously treat several potential aetiologies of chronic IC.

Lower urinary tract symptoms may also be associated with diabetes mellitus type 2 (DM2) and given the client’s urinary tract symptoms, dietary habits, and sedentary lifestyle, this differential diagnosis was an important consideration. Although Rose described increased urinary frequency and urgency, she did not describe polyuria (increased urine volume) commonly associated with DM2. Rose’s symptoms included a lack of thirst and decreased water intake, as well as normal range blood pressure. In DM2 there is commonly increased thirst and water intake, and elevated blood pressure. Therefore, although undiagnosed, the client’s symptom profile was considered to correlate more closely with those of IC, and short-term treatment aimed to address these symptoms and their underlying drivers.

There is a positive association between stress and abnormalities of the HPA axis, and an increase in the occurrence of bladder symptoms, as well as an increase in intensity and severity of existing symptoms, such as pain and urgency. Chronic stress has been linked with a wide array of adverse health outcomes, many of which are chronic in nature, and complicated by chronic inflammation. Supporting the nervous system to reduce excessive stress and anxiety to improve mood and potentially inflammation was pivotal in the successful management of this case.

Antidepressants are sometimes utilised in the medical treatment of IC based on the inhibition of the synaptic reuptake of serotonin and norepinephrine. This treatment may also improve mood, and pain perception. The tricyclic amitriptyline is commonly recommended and has been effective in reducing symptoms of pain and urgency intensity. Amitriptyline decreases mast cell activity and blocks H1-histaminergic receptors; however, its use is also commonly associated with significant side effects of dry mouth, dizziness and gastrointestinal complaints in up to 88% of patients. Research indicates low acceptability in the use of amitriptyline, with higher dropout rates than comparators, despite findings of superior effect. Many people prefer treatment options with fewer side effects.

Herbal medicines with demonstrated efficacy for reducing depression and improving mood may provide a natural alternative without the side effects of pharmaceuticals for treatment of IC. The action of Crocus sativus may increase synaptic clef serotonin concentration and reduce neuroinflammation and Hypericum perforatum has been found to have clinical efficacy comparable to selective serotonin reuptake inhibitors (SSRIs) in symptoms of depression. Adaptogens, or herbal medicines that may improve resilience such as Eleutherooccus senticous and Schisandra chinensis, were used traditionally in herbal medicine to regulate stress response and provide additional benefits of increasing concentration, performance, and endurance in fatigue states. Scutellaria lateriflora was traditionally used as a nervous and anxiolytic; however, its additional anti-inflammatory, spasmyolytic, antimicrobial, and antioxidant actions, may all have further benefited this client.

The prescription of Herbal Mix 1 aimed to reduce symptoms by supporting the client’s nervous system, regulating neural pathways and stress responses to improve mood, decrease anxiety and increase the client’s sense of control over her body and health.

Herbal Mix 2 was prescribed to reduce urgency and frequency of urinary tract symptoms.

Inhibition of inflammatory cascades and mast cell stabilisation associated with extracts from Boswellia serrata may reduce inflammation and halt complex feedback loops associated with IC, decreasing urinary urgency and frequency and inhibiting the formation of oxygen radicals capable of causing further inflammation and damage to the urinary tract. Zingiber officinale and Curcuma longa also inhibit multiple pro-inflammatory pathways particularly relevant in IC and possess sound safety profiles.

The holistic nature of naturopathy in case analysis and treatment decisions and its consideration of the interdependence of all body systems including exacerbating and compensating factors, is well suited to the treatment of complex and chronic disease states. The broad scope of the naturopathic consult and resultant treatment plan (a unique treatment approach informed by individual case characteristics) may provide treatment at multiple levels at the same time. In this case, herbal medicines, dietary changes and the inclusion of self-care rituals and behaviours were used to empower and engage the client, reduce inflammation and stress, balance nervous system physiology, and improve urinary tract symptoms and risks of progressive disease.

This case study provides an example of the potential benefits of a naturopathic approach and the importance of treating the nervous system and applying stress.
management, as well as effective treatment of symptoms in people with complex and chronic physical conditions.

Limitations of this case include uncertainty regarding exactly which parts of the complex treatment correlate with the therapeutic effects. Naturopathic treatment involves extended consultations, active listening and validation of the client’s concerns. This incidental counselling may provide therapeutic effect, which has not been directly accounted for in this case study. Another limitation is the short time frame of the case management. This case spans two weeks of treatment and long-term effectiveness has not been described; nevertheless, the significant alleviation of symptoms and the subsequent improvement in quality of life in that time warrant dissemination and discussion.

This case highlights the broad-ranging actions of herbal medicines, from their many and varied constituents, potentially providing benefits at multiple levels, addressing symptomology and interdependent aspects of pathophysiology, which remain poorly understood.

Conclusion

This case describes the benefits of treating symptoms of IC with naturopathy where the treatment strategy was underpinned by naturopathic philosophy and addressed the complex interplay of aspects relevant in a person with chronic disease. Despite the multifactorial aetiology of IC, herbal medicine addressed the presenting complaints and associated conditions in a prompt and timely manner.

Note

* The patient’s name has been changed to preserve her anonymity.

References

A synopsis of the 2018 International Congress on Integrative Medicine and Health

Bradley Leech BHSc Nut Med (Hons)\textsuperscript{a,b}, Jessica Bayes BHSc Nut Med (Hons)\textsuperscript{b}
\textsuperscript{a} University of Technology Sydney, Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, Ultimo, NSW, Australia
\textsuperscript{b} Endeavour College of Natural Health, Office of Research, Fortitude Valley, QLD, Australia

Contact information
Bradley Leech, University of Technology Sydney, Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, 15 Broadway, Ultimo, NSW, 2007, Australia
Email Bradgleech@gmail.com

Abstract
The 2018 International Congress on Integrative Medicine and Health (ICIMH) took place in Baltimore, America, and focused on the advancement of integrative health through research, education, clinical practice and policy. The Congress served as a platform to share novel research in integrative medicine and health. Major themes of the 2018 ICIMH include the mechanism of action behind traditional and complementary therapies, mindfulness and non-pharmaceutical pain management techniques. Throughout the Congress, trends were seen suggesting a new paradigm of health care is necessary, moving away from solely conventional medicine to an integrative approach, utilising manual therapies, mindfulness practice and dietary interventions in conjunction with conventional care. Delegates who attended the 2018 ICIMH networked with international researchers and health care practitioners, forming new relationships and strengthening pre-existing partnerships.

Introduction
The 2018 International Congress on Integrative Medicine and Health (ICIMH), organised by the Academic Consortium for Integrative Medicine and Health, was held 8–11 May 2018 in Baltimore, Maryland, America. The focus of the 2018 ICIMH was to advance integrative health through research, education, clinical practice and policy.

The 2018 ICIMH attracted many health care practitioners, researchers, educators and policy advocates from over 25 countries. During the Congress, hundreds of poster presentations and over 70 concurrent symposia, panel discussions and oral presentations were held. While a wide range of topics were discussed and presented at this Congress, a number of trends were apparent, including the mechanism of action behind traditional and complementary therapies, mindfulness and non-pharmaceutical pain management techniques. Validation of traditional therapies such as Ayurveda, traditional Chinese medicine, acupuncture, yoga, tai chi and mindfulness were seen throughout many of the poster sessions and a key focus for presenters. One other theme seen at the 2018 ICIMH was the need for a new paradigm, moving away from solely pharmaceutical treatments to an integrative approach, utilising manual therapies, mindfulness practices and dietary interventions, in conjunction with conventional care. Numerous researchers highlighted the importance of an integrative approach in clinical practice for the management of chronic diseases such as Alzheimer’s disease, cancer, autoimmune conditions and debilitating symptoms such as pain.

Highlights from the oral presentations
Helene Langevin (Osher Center for Integrative Medicine) received a standing ovation after presenting the preliminary results of her research on connective tissue. Her recent research into the mechanism of action behind stretching and the reduction of acute inflammation had the audience in captured attention. Most insightful were the preliminary results from animal models that suggest stretching may reduce cancer growth (manuscript accepted for publication). Further human studies are necessary to translate these results into human application.

The 2018 ICIMH reminded us of the importance of the microbiome, intestinal integrity and inflammation for optimal health, with Alessio Fasano (Center for Celiac Research and Treatment) giving an engaging and informative presentation on chronic inflammatory diseases and their relationship to the health of the gastrointestinal system.

Steven Woolf (VCU Center on Society and Health) discussed numerous topics surrounding population health. One of which is the fact that an individual’s postcode (location) can influence their life expectancy\textsuperscript{1}. Steven Woolf’s presentation illustrates why an integrative approach requires practitioners to consider not only one’s genetic make-up but also their postcode during a health assessment.

© NHAA 2018
The role of nutrition and the anti-inflammatory diet in paediatric medicine was discussed by Diane Barsky (Children’s Hospital of Philadelphia). The anti-inflammatory diet, which combines aspects from both the Mediterranean and Asian diets, can be used to improve health and prevent chronic disease. An emphasis was placed on the importance of implementing good eating habits from a young age in order to prevent chronic disease in later life. Practical advice on how to incorporate these changes into a household setting in conjunction with healthy lifestyle habits was also discussed.

Further adding to the theme of mind–body medicine was the symposium on “Interoception, Meditation, and Pain”, which explored the ability of the brain to consciously sense the physiological state of the body. The importance of developing interoception skills was discussed in relation to reporting clinical outcomes. The take-home message from this symposium was that meditative practices often employ techniques to heighten and enhance the interoceptive experience, which can be useful when treating patients with chronic pain.

Suzanne Grant and Jennifer Hunter (National Institute of Complementary Medicine) spoke about the integrative oncology services available in the Australian health care system. The services were compared with other Western countries including Canada, America and the United Kingdom. Through this comparison, Australia appears to be lagging behind in providing integrative oncology services in the health care system. The presenters further discussed the barriers to overcome to incorporate traditional and complementary medicine into the health care system of Australia.

Poster sessions

The poster sessions provided a unique platform for researchers to engage with other academics and health care practitioners. Attendees were able to ask questions and participate in active discussions with poster presenters in order to gain further insights into the latest integrative health research. This approach allowed for a personalised delivery and provided an atmosphere of collaboration, bridging the gap between health care practitioners and researchers.

The poster presentations followed similar underlying themes to the oral presentations, with a focus on mindfulness practice, non-pharmaceutical pain management and the importance of adopting an integrative approach to health care. A range of different professions were represented among the various posters, including acupuncture, herbal medicine, manual therapies, naturopathy and nutrition. A considerable amount of research on yoga and breathing techniques was also presented during the poster sessions. The comprehensive display of poster presentations, coupled with the unique presentation platform, highlighted the importance of partnerships between different health care practitioners and also the role of integrative health in a wider health care setting.

Australian researchers

Australian researchers and academics from the University of Technology Sydney, Endeavour College of Natural Health and Western Sydney University presented on numerous advancements in the area of integrative medicine, including intestinal permeability in clinical practice, folate absorption, integrative oncology, naturopathic education, Australian complementary and integrative practitioner specialisations and disclosure of complementary medicine use in chronic disease. These research topics highlight a small portion of the research currently being conducted within Australia. The Australian delegates who attended the 2018 ICIMH networked with international researchers and health care practitioners, forming new relationships and strengthening pre-existing partnerships.

Concluding remarks

The major take-home message from the 2018 ICIMH includes the significance and effectiveness of traditional therapies on optimal health and their potential application within the health care system here in Australia. There is also a trend in the research community to validate and understand the mechanism of actions of Ayurveda, traditional Chinese medicine, acupuncture, yoga, tai chi and mindfulness. Furthering the understanding of the ‘how’ behind traditional and complementary medicine provides the foundations to incorporate these therapies into a larger health care setting.

We look forward to attending the 14th International Congress on Complementary Medicine Research (ICCMR) hosted by Endeavour College of Natural Health in Brisbane 7–10 May 2019. The theme of the Congress is Pathways and Partnerships, bringing together researchers and practitioners from an array of disciplines within complementary medicine.

Acknowledgement

BL would like to acknowledge the support of the Australian Government Research Training Program Scholarship.

Conflict of interest

None.

References


The 11th
Herbal and Naturopathic Medicine
International Conference

29-31 MARCH 2019

MEET OUR INTERNATIONAL KEYNOTE SPEAKERS

TRADITIONAL WISDOM, FUTURE PRACTICE

Pullman Melbourne Albert Park
65 Queens Road, Albert Park VIC

TINA HAUSSER
Heilpraktikerin (HP), ND
1st Vice President, World Naturopathic Federation, Spain

SANDRA CLAIR
Herbalist and medical anthropologist
Artemis, New Zealand

PROF MICHAEL HEINRICH
Pharmaceutical biologist, pharmacognosist and anthropologist
Centre for Pharmacognosy and Phytotherapy, UCL School of Pharmacy, London (UK)

DR FRANCESCA PANZIRONI & NGANKARI HEALERS
Anangu Ngangkari Tjutaku Aboriginal Corporation

REGISTER ONLINE. MEMBER DISCOUNT APPLIES.
ATTEND 3-DAYS AND YOUR CPE IS DONE FOR 2019!

www.nhaaconference.org.au

© NHAA 2018
Dairy consumption and cardiovascular disease and mortality


Cardiovascular disease is the leading cause of mortality worldwide, with an estimated 80% of the burden from low- and middle-income countries. Dietary guidelines commonly recommend minimising the consumption of whole-fat dairy products for cardiovascular disease (CVD) prevention as they are a source of saturated fats and presumed to adversely affect blood lipids and increased CVD and mortality. The evidence for this is limited. Furthermore, the beneficial compounds of dairy and dairy fat may also influence health outcomes. The current study aimed to assess the associations between total dairy intake and specific types of dairy products with mortality and major cardiovascular disease.

The Prospective Urban Rural Epidemiology (PURE) study is a large, multinational cohort study of individuals aged 35–70 years, enrolled from 21 countries in five continents. Dietary intakes of dairy products were recorded using country-specific food frequency questionnaires (FFQ). Dairy consumption was considered as whole-fat or low-fat, with products comprised including milk, yoghurt, and cheese. Case-report forms were used to record data for major cardiovascular events and mortality during follow-up. The primary outcome was the composite of mortality or major cardiovascular events (defined as death from cardiovascular causes, non-fatal myocardial infarction, stroke, or heart failure). In the present study, outcome events until 14 July 2018 were included.

A total of 153,220 participants completed the FFQ, of which some were excluded due to implausible energy intakes and/or history of CVD at baseline. In total, 136,384 individuals were included in the study. During the median follow-up period of 9.1 years, 10,576 (7.7%) composite events were recorded (deaths n=6796 and mortality or major CVD events n=3780). Total dairy intake was higher in Europe and North America, the middle East, and South America than in other regions. There were inverse associations between total dairy consumption and mortality or major CVD events. A higher intake of total dairy (>2 serves per day compared to no intake) was associated with lower risk of composite outcome, non-cardiovascular mortality, cardiovascular mortality, major CVD, and stroke. The risk of stroke was markedly lower with higher dairy consumption. No association with myocardial infarction was observed. Higher intake of milk and yoghurt was associated with lower risk of the composite outcome, whereas cheese intake as not significantly associated with the composite outcome.

Authors concluded their findings support the dairy product consumption might be beneficial for mortality and CVD, especially stroke. Being a large, multinational cohort study, the findings have relevance across a broader population and are strengthened by the population size. Limitations include the use of FFQ and potential errors in measurement recording or data collection. Furthermore, as an observational study, the findings do not confirm causality. The findings provide clinically relevant information regarding dairy consumption and cardiovascular risk profiles, with the suggestion that consumption of dairy products should not be discouraged.

Low FODMAP diet and infantile colic

Jacakovu M, Craig SS, Yelland GW, Barrett JS, Gibson PR, Muir JG. Randomised clinical trial: reducing the intake of dietary FODMAPs of breastfeeding mothers is associated with a greater improvement of the symptoms of infantile colic than for a typical diet. Aliment Pharmacol Ther 2018;48:1061–1073

Infantile colic is a common medical condition estimated to affect approximately 14–30% of infants. It is a common cause of emergency department presentations, as well as being associated with cessation of breastfeeding and post-natal depression. Colic is defined as per the Wessel criteria as paroxysmal crying episodes lasting for >3h/d, >3d/week and for ≥3 weeks. While infantile colic spontaneously resolved by about 3–4 months and despite a lack of evidence of therapeutic diets, many breastfeeding mothers will avoid ‘windy’ foods in attempt to improve colic. The current study aimed to investigate the effects of a maternal low-FODMAP (fermentable, oligosaccharides, disaccharides, monosaccharides, and polyols) diet compared to a typical-Australian diet on infant crying and fussing durations of infants with colic.

The study was a randomised, double-blind, crossover study conducted between 2014 and 2016. Infants who were exclusively breastfed, were aged ≥9 weeks and who met the Wessel criteria for infantile colic were included. Mothers were provided with a 10-day low-FODMAP or typical-Australian diet, then alternated to the other dietary intervention without a washout period. Infants without colic were used as a control group who maintained a habitual diet. The primary endpoint was...
change in duration of infant crying and fussing at end of dietary intervention. Secondary endpoints included duration of infant feeding, sleeping and periods of awake and content, maternal wellbeing, and faecal and breast milk indices were measured.

Of the 180 pairs of mothers and colicky infants assessed for eligibility, only 17 were recruited, largely due to not meeting inclusion criteria. Of these, 14 were randomised to treatment and 13 completed both dietary arms and had evaluable data. At baseline, crying-fussy times of infants with colic was 269 minutes, compared to 91 minutes in infants without colic. Crying-fussy duration was significantly reduced by a median of 23% during the low-FODMAP diet compared with 20% during the typical-Australian diet. No difference was observed regarding dietary intervention order. No significant changes in breast milk or infant faecal indices were noted. Maternal anxiety and stress reduced with the typical-Australian diet, but remained stable on the low-FODMAP diet.

The study provides interesting findings with a low-FODMAP diet being associated with a clinically significant improvement in crying-fussing durations of infants with colic compared with a typical-Australian diet. These findings should be considered with recognition of the small sample size; however, given the small duration of intervention, the study suggests there may be a benefit in trialling a low-FODMAP diet in breastfeeding mothers who have an infant with colic. Future research to understand the mechanism of effect, and any wider implications on maternal wellbeing and infant behaviour would be valuable.

**ART-conceived adolescents and arterial hypertension**


The use of assisted reproductive technologies (ART) has grown considerably over the past decades and now accounts for 2–5% of births in developed countries. Over six million persons have been conceived by ART worldwide. There is evidence that ART alters the cardiovascular phenotype in apparently healthy children and mice, including premature vascular ageing. The long-term outcomes of altered cardiovascular phenotype in children are unknown. The authors hypothesised that vascular alterations may persist in ART-conceived adolescents and that hypertension may be the first detectable clinically relevant endpoint.

Five years after the initial study into cardiovascular phenotyping in ART-conceived humans, participants were invited to participate in the follow-up. The current study reassessed vascular function in 54 young, apparently healthy, ART-conceived adolescents and in 43 age- and sex-matched controls and evaluated 24-ambulatory blood pressure (BP). Vascular function, arterial stiffness and structural alterations were also measured and documented. The control group involved school friends of the ART-conceived children, with the rationale to best match for potential confounding factors including socio-economic background, physical activity, and interests in sport. All participants were born at term, had a normal birth weight and none of the pregnancies were complicated by pre-eclampsia.

Body mass index was comparable in ART and control participants, and serum markers were comparable between groups and within normal limits. None of the participants had structural heart disease as assessed by echocardiography. Premature vascular ageing persisted in the ART-conceived adolescents at the five-year follow-up. This seemed to be related to endothelial dysfunction, increased vascular stiffness, and altered vascular wall morphology. Importantly, 24-h systolic as well as diastolic BP was markedly higher in the ART group than control. Of the ART participants, 8 of the 52 met the criteria for diagnosis of arterial hypertension (>130/80mmHg and/or >95th percentile) whereas only one of the control participants fulfilled the criteria. BP variability was also markedly higher in ART-conceived subjects that in control subjects.

ART has allowed for millions of infertile couples to have children; however, the long-term health effects should also be taken into account. Increasing evidence suggests altered cardiovascular phenotypes and the results of this study demonstrates persistent premature vascular ageing into adolescence that progresses to increased arterial BP. The long-term consequences on cardiovascular risk and outcomes remain unknown. The study includes only a relatively small number of ART-conceived adolescents, so whether this is representative of a broader ART-population is unclear. Ongoing follow-up studies, and larger population studies will provide further insight in the future.

**Omega-3 supplementation during pregnancy reduces preterm births**


Preterm birth (born before 37 weeks’ gestation) is a leading cause of disability and death in the first five years of life. Omega-3 long-chain polyunsaturated fatty acids (LCPUFA) is a commonly used supplement and dietary component during all stages of life. Previous research has found a higher intake of foods containing omega-3 LCPUFA, such as fish, during pregnancy to be associated with longer gestation and improved perinatal outcomes. The aim of the current review was to assess the effects of omega-3 LCPUFA, as supplements or as dietary additions, during pregnancy on maternal, perinatal, and neonatal outcomes and longer term outcomes for mother and child. A Cochrane review on omega-3 intake during pregnancy was previously undertaken in 2006, and this review is an update on the previous publication.
In August 2018, the authors completed a literature search with 70 randomised controlled trials (RCTs) included in the review, with a total of 19,927 women at low, mixed, or high risk of poor pregnancy outcomes. Studies compared omega-3 interventions as food or supplements to placebo or no intervention. The quality of evidence included varied from high to very low, with overall mixed level of bias. Most trials were conducted in middle-upper or high-income countries, with a large number of trials including women at increased risk of preterm birth.

Preterm birth (<37 weeks) and early preterm birth (<34 weeks) were significantly lower in women who received omega-3 LCPUFA compared with no omega-3. Prolonged gestation (>42 weeks) possibly increased from 1.6% to 2.6% women in those who received omega-3 compared to those who did not. Outcome perinatal data demonstrated a possible reduced risk of perinatal death and possible reduction in neonatal care admissions. A reduced risk of low birthweight babies but possible increase in large-for-gestational age babies was reported for omega-3 supplementation. Insufficient evidence was available to assess maternal outcomes such as post-term induction, maternal serious adverse events, maternal admission into intensive care, or postnatal depression.

The authors concluded that omega-3 LCPUFA supplementation during pregnancy to be an effective strategy for reducing the incidence of preterm birth, noting that it may increase the incidence of post-term pregnancies. A sufficient evidence base has been established for omega-3 supplementation during pregnancy, compared to placebo or no intervention; however, additional studies into varying types of omega-3 PUFA, timing and dose optimisation may further understanding and best clinical practice.

**Mediterranean diet and stroke risk**


Stroke is a leading cause of health burden, contributing to a significant amount of disability and mortality. It is estimated that up to 90% of stroke risk is preventable and attributable to modifiable factors including diet. The Mediterranean diet (MD) is a well-researched diet and has been demonstrated to be beneficial for numerous health outcomes, including stroke prevention. Previous studies on the MD and stroke have focused on high-risk cardiovascular disease (CVD) groups or without stratification of CVD risk factors. The current study aimed to look at the role of MD in a broader population of middle and older aged people, and to better understand whether any associations differ between men and women, the associations between different CVD risk categories, and the individual components of the MD with stroke risk.

The prospective study involved participants from the European Prospective Investigation into Cancer study in the UK, which included a baseline cohort of 23,232 men and women aged 40 to 77 years. Participants completed a health and lifestyle questionnaire and attended a health examination. The adherence to an MD diet was established using seven-day diet diaries completed with consideration of protective items including fruit and nuts, vegetables, fish, moderate alcohol intake, and higher unsaturated: saturated fat intake. Stroke incidence (fatal and non-fatal) was recorded and linked through hospital records and death certification information. Risk of incident stroke was calculated in the whole population, and also stratification by sex and CVD profile, using the Framingham risk score.

Of the 22,232 participants with a mean age of 59.1 years, 2009 incident strokes occurred during the follow-up period of 17.0 ± 4.6 years (mean). Risk of stroke was significantly reduced with greater adherence to the MD across the whole study population. After stratification by sex, these associations remained in women, but not men. In women, even a moderate adherence to MD was associated with a significant reduction in stroke risk, but again, this was not observed in men. Higher adherence to the MD was associated with reduced stroke risk, particularly in participants at high cardiovascular risk as based on Framingham risk score. No significant risk reduction was observed in the subgroup with low cardiovascular risk. Individual components of the MD that were associated with the risk reduction included vegetables and moderate alcohol intake.

Strengths of the study include the prospective design, long-term follow-up, consideration of a number of other stroke risk factors, and being representative of a larger population; however, it should be noted that the population was predominantly wide and may not be generalisable to different populations. Limitations include that dietary assessment was only undertaken at baseline, not accounting for atrial fibrillation as a risk factor.

The study provides interesting findings that are relevant at a population-based level, demonstrating that greater adherence to the MD was associated with lower risk of stroke. When considering sex stratification, only women were found to have MD associated with significantly reduced stroke risk, although the risk for men was down trending. While there are a variety of benefits that gave been associated with the MD, assessing the effect across different sub-groups of population enables the understanding of where it may be of most benefit.

**Genetics, lifestyle and stroke risk**


Stroke is a leading cause of morbidity and mortality worldwide and is associated with a number of risk factors, including diet and lifestyle. A role in genetics has also been established from twin studies, family history studies...
and, more recently, genome-wide association studies. Our understanding about whether adhering to a healthy lifestyle could attenuate the effect of genetic background on risk of incident stroke is currently unknown. The present study investigated whether a weighted genetic risk score correlated with a stroke incident in a large population, and whether adherence to a healthy lifestyle influenced this association.

The prospective, population-based cohort study used data from the UK Biobank, which includes participants aged 40–69 years and collects extensive health data from a variety of methods. The main outcomes and exposures of interest in this study were imputed genetic data, incident stroke, and lifestyle factors. Inclusion criteria included all who were classified as white British, without a history of stroke or myocardial infarction, and with complete data on lifestyle. Genetic data was used and a polygenic risk score was derived using data from MEGASTROKE, a large meta-analysis of genome-wide association studies. Adherence to a healthy lifestyle was determined on the basis of four factors: non-smoker, healthy diet, body mass index (BMI) <30kg/m^2, and regular physical exercise. The main outcome was incident of stroke and associations with genetic risk and lifestyle factors.

Complete data was available for 306,473 participants with a median follow-up period of 7.1 years. Over this period, 2077 incident fatal or non-fatal strokes were reported as first incident vascular event or death. The risk of incident stroke was 20% and 35% higher for intermediate and high genetic risk scores, respectively compared to those at low genetic risk. These associations were independent of lifestyle profile. The genetic risk score was significantly associated with systolic blood pressure, diastolic blood pressure, lipid lowering drugs, and diabetes, but not with BMI. Unfavourable lifestyle was defined as one or less of the favourable factors was associated with a 66% increased risk of stroke compared with a favourable lifestyle (defined as three or more favourable factors). A high genetic risk combined with an unfavourable lifestyle profile was associated with more than a twofold increase risk of stroke compared with a low genetic risk and favourable lifestyle.

Strengths of the study include its large sample size, allowing for thorough investigation of genetics and lifestyle factors in detail. Limitations include the narrow range of lifestyle and behavioural changes after baseline not being well accounted for. Furthermore, the study population was limited and may not be generalisable to a broader population. The study provides interesting and relevant findings, highlighting the risk of genetics and lifestyle in stroke risk, and also highlights the potential of healthy lifestyle interventions to reduce risk, across even high genetic risk profile.

### Brain age from electroencephalogram of sleep


Human sleep patterns are known to undertake robust and predictable changes with age that are observable in overall sleep architecture and electroencephalogram (EEG) oscillations/waveforms. Changes include earlier to sleep and earlier waking, shorter sleep duration, increased sleep fragmentation, and altered rapid eye movement (REM) sleep and non-REM sleep. On EEG, older persons exhibit changes in slow wave during deep sleep, changes in spindle amplitude, density and duration, and changes in the coupling of spindles and slow oscillations. The changes on EEG may be considered as representing a ‘brain age’ (BA), with the potential to act as an ageing biomarker by comparing BA variation between individuals of the same chronological age. The authors of the current study aimed to develop a model to predict to predict BA based on two large sleep EEG data.

The retrospective analysis included data sets from two large studies: the Massachusetts General Hospital (MGH) sleep lab data set (n=2532); and the Sleep Heart Health Study (SHHS) (n=1974). Participants in the MGH study were aged 18–80 years (median 50), while participants in the SHHS study were aged 40–80 years, with a median age 58 years at first visit and 64 years at second visit. Participants included underwent diagnostic polysomnogram (PSG) and had a clinical diagnosis available from five years before to one year after the PSG from the hospital database. Patients were defined as having significant neurological or psychiatric disease if they had at least one neurological or psychiatric diagnosis during the same period. To predict age, authors extracted a number of features from the sleep EEG and created a model to predict BA comparing against chronological age.

In total, 2532 participants were included in the analysis, of whom 167 had significant neurological or psychiatric disease. The model prediction tool obtained a mean absolute deviation of 7.6 years between BA and chronological age in healthy participants from the MGH data set. Advancing age was tracked using a subset of participants from the SHHS data set that had two visits over average 5.2 years, that was associated with an average 5.4-year increase in BA. The study reported a mean excess BA in participants with significant neurological or psychiatric disease of four years relative to healthy controls. Participants with hypertension and diabetes were also associated with an excess BA.

The authors note that EEG-based BA may offer some potential advantages to assessing aging in that it reflects functional changes, is participant friendly, and is readily repeatable to assess intervention effect. Furthermore, it was suggested the study presents preliminary findings that excess BA to chronological age reflects underlying brain pathology. Further research is required to understand the role of EEG-BA as a potential biomarker of brain age and health.
Reviews of articles on medicinal herbs

Dr Wendy McLean

These abstracts are brief summaries of articles which have appeared in recent issues of herbal medicine journals, some of which may be held in the NHAA library.

Saffron therapy for the treatment of mild/moderate age-related macular degeneration


Age-related macular degeneration (AMD) is the most common cause of irreversible visual loss in the developed world. Despite recent advances in the treatment of AMD, therapeutic options are limited. Dietary modification and nutritional augmentation with supplements trialled in the Age Related Eye Diseases Study (AREDS) remain the basis of AMD management. Saffron (Crocus sativus) is a well-known Middle Eastern spice that has antioxidant and anti-inflammatory properties that may be effective for AMD. In the current study, the efficacy of saffron for AMD is investigated.

A prospective, randomised, placebo-controlled, double-blind, crossover trial including 100 participants attending a single tertiary retinal clinic was conducted between January 2013 and March 2015. Inclusion criteria were age ≥50 years, moderate severity of AMD (defined as AREDS grade 2 or 3) affecting at least one eye and best corrected visual acuity (BCVA) better than 55. Early Treatment of Diabetic Retinopathy Study (ETDRS). The diagnosis of AMD was confirmed by both dilated retinal examination and dilated retinal fundus photography.

Participants were randomised to one of two arms, either 20 mg saffron or placebo for 90 days. After initial three-month period, all participants crossed over into the other arm and received treatment with the other intervention (saffron or placebo, as appropriate) for a further three months. Participants were requested to maintain their normal diet and continue on any supplements (including AREDS-based therapies). Participants underwent monthly ophthalmic examination for: (a) intraocular pressure (IOP) monitoring via Goldmann Applanation Tonometry, (b) adverse event monitoring, (c) standardised BCVA assessment in ETDRS letters and (d) colour fundus photography. Additionally, at the baseline, three- and six-month visits, participants also underwent flicker perimetry (FP), microperimetry (MP), SD-OCT, FAF, lens grading using AREDS lens assessment criteria and multifocal electroretinogram (mERG) assessment.

Of the 100 participants, 97 completed both the initial and crossover phases of the study. Fifty-one participants were male (52.6%), the mean age of participants was 73.9 years. Seventy-one participants (73.2%) were already consuming AREDS supplements and were evenly distributed in the saffron and placebo groups. Saffron significantly improved mean BCVA 0.69 letters (p = 0.001) and reduced mean-pooled mERG latency by 0.17 ms (p = 0.04) compared to placebo. Amongst participants on AREDS supplements, mean BCVA improved 0.73 letters (p = 0.006) and mean pooled mERG response density improved 2.8% (p = 0.038). There was no significant difference in adverse event occurrence between groups (p > 0.10).

Oral saffron supplementation modestly improved visual function in participants with AMD, including those using AREDS supplements. Some limitations apply to this study: namely the small sample size, short follow-up period and lack of reliable biomarkers available to test the response of AMD to saffron. However, given the increasing prevalence of AMD, and its propensity to lead to irreversible vision loss, further, longer duration studies are justified to investigate role of saffron in treating AMD.

Effects of Rhodiola rosea supplementation on mental performance, physical capacity and oxidative stress biomarkers in healthy men


The adaptogenic properties of Rhodiola rosea (Rhodiola) are attributed to the biologically active substances in its root including flavonoids and phenolic glycosides (salidrosides and rosavins). These compounds potentially enhance physical and mental performance and reduce fatigue. The mechanism of Rhodiola’s adaptogenic effect are thought to be due to regulation of the hypothalamus-pituitary-adrenal (HPA) axis and key mediators of the stress response including cortisol. In addition, Rhodiola has demonstrated its ability to scavenge free radicals shown in vitro and in animal studies. Strenuous exercise increases oxidative stress in the body, and exercise-induced oxidative stress in blood, liver and skeletal muscle has been shown in animal studies to be reduced by Rhodiola.

The results of studies to date investigating the adaptogenic effects of Rhodiola in humans have been ambiguous, and may in part be due to doses used and the length of clinical trials. The majority of human studies have used low-dose extracts (100–200 mg) while higher doses (≥600 mg) have only been used for short durations.
suggest Rhodiola’s effect on cognitive performance and in healthy males after exercise. Some studies also of the current study did not show any significant to effects on cortisol secretion; however, the results suggest the anti-fatigue effect of Rhodiola may be due following Rhodiola ingestion. Results of animal studies for improving the cognitive and/or neural performance physically active men.

Physiological outcomes in patients with NAFLD. Recent evidence suggests that plant-derived natural products, such as flavonoids and polyphenols, may be promising in non-alcoholic fatty liver disease (NAFLD) management by reducing liver enzymes and acting as an antioxidant and anti-inflammatory. Green tea, derived from leaves of Camilla sinensis, is rich in polyphenols including catechin, epicatechin gallate and epigallocatechin-3-gallate and has been used in traditional medicine for the treatment of metabolic disorders, including hypertension, obesity and cardiovascular disease. Clinical trials investigating green tea for NAFLD have produced conflicting results, so the aim of the current meta-analysis was to collate and evaluate the effect of green tea supplementation on metabolic outcomes in patients with NAFLD.

Databases including MEDLINE, Google Scholar and ISI Web of Knowledge were searched. The review included clinical trials that included patients with a history of NAFLD or NASH and evaluated the use of green tea supplementation in any dosage or form. Studies were excluded if green tea was used as an adjuvant or trial periods were less than two weeks. The meta-analysis was completed using a random-effects model.

In total, six studies met the inclusion criteria and were included in qualitative assessment. Four articles were included in the meta-analysis. In the six studies, 256
participants were included with a mean age of 55 years. The duration of randomised controlled trials ranged between 84 and 180 days, and the mean dosage of green tea intervention was approximately 700 mg/day. All studies were parallel controlled trials and were published between 2006 and 2017. NAFLD was diagnosed and confirmed by ultrasonography, liver biopsy and liver enzyme levels. AST and ALT were the main biomarkers in all studies, and biomarkers of insulin resistance and serum lipids were also reported.

The meta-analysis of data from four studies indicated significant effects of green tea supplementation in altering alanine and aspartate blood concentrations. Likewise, a favourable effect of green tea administration was observed on body mass index, triacylglycerol, total cholesterol and low density lipoprotein cholesterol, whereas no significant effect was detected on high-density lipoprotein cholesterol concentrations and homeostasis model assessment of insulin resistance. Based on animal and human studies, the authors propose several therapeutic mechanisms of action for green tea for NAFLD including its antioxidant, hypolipidaemic and anti-inflammatory effects. Green tea was found to be safe, as serious adverse effects were not reported among the studies included. Green tea supplementation up to 1.944 mg/day has been demonstrated to not cause adverse effects.

There were a number of limitations to this meta-analysis, including the small number of eligible trials, and the heterogeneity among trials in regard to study design, dosage and duration of intervention. To better understand the efficacy of green tea for NAFLD, long-term intervention trials with varying dosage supplementation are required.

**Saffron (Crocus sativus) versus duloxetine for the treatment of patients with fibromyalgia**


Fibromyalgia is a chronic debilitating disorder that affects 1–10% of the population, mostly women. The disorder is characterised by chronic pain accompanied by other symptoms including fatigue, sleep disturbances, anxiety/depression, cognitive dysfunction and other somatic symptoms. Major depressive disorder is common in fibromyalgia suffers, affecting 22–90% of these individuals. This is not surprising, given the aberrant neurobiological findings which are common to the pathogenesis of both conditions. Lowered serotonin and norepinephrine levels have been identified as possible mechanisms of pathophysiology of both chronic pain and mental symptoms in fibromyalgia, potentially complicated by decreased antioxidant capacity. Conventional medications, such as the norepinephrine serotonin reuptake inhibitor (NSRI)
duloxetine, are recommended as standard therapy to reduce symptoms in fibromyalgia patients; however, limited efficacy, poor tolerability and low adherence has been reported, suggesting a clinical need for treatment options in addition to pharmaceutical antidepressants. Therefore, interest remains in alternative therapies that are better tolerated and have greater efficacy. Clinical trials have demonstrated that saffron (Crocus sativus) has antidepressant and anti-anxiety effects, and animal studies have shown promising effects for chronic pain. The aim of the current study was to compare the efficacy and safety of saffron with duloxetine in treatment of patients with fibromyalgia.

The study was a double-blind randomised control trial that compared saffron against duloxetine at an outpatient rheumatology clinic, Imam Khomeini Hospital, Tehran, Iran. Participants were men and women who were diagnosed with fibromyalgia based on the American College of Rheumatology (ACR) 2010 criteria and had a pain score of over 40 out of 100 based on the visual analogue scale (VAS). Exclusion criteria included co-morbid rheumatologic diseases, inflammatory/infectious/autoimmune arthritis, co-morbid neuropsychiatric disorders except depressive disorders, pain due to traumatic injuries, drug history of duloxetine or saffron use, current use of psychoactive medications, recent use of muscle relaxants, steroids, opioid analgesics, benzodiazepines, anti-epileptics, or injective analgesics. Subjects were given either one capsule of saffron (15 mg) or duloxetine (30 mg) for the first week, and two capsules per day from week 2 to week 8. Primary outcomes included differences between groups for the mean scores of the Hamilton Rating Scale for Depression (HRSD), Fibromyalgia Impact Questionnaire (FIQ), and Brief Pain Inventory (BPI) pain score. Secondary outcomes were changes in pain Visual Analogue Scale (VAS), Hospital Anxiety and Depression (HADS) subscales. Time of treatment interaction effect was assessed for all scales.

Fifty-four patients were recruited into the study, with 27 participants randomly assigned to each treatment group and 23 (per group) completing the trial. Baseline characteristics were comparable between groups, with the exception of marital status. Primary and secondary outcomes were also comparable at baseline. At the end of the trial, all scores had decreased in both groups. There were no significant differences detected between groups for any scales in terms of score changes from baseline to endpoint (p-values: 0.182–0.900) nor in terms of time of treatment interactions (p values: 0.209–0.964). No significant difference was detected between the two arms for the adverse events.

The authors conclude that saffron was equivalent to duloxetine for treating mental and physical symptoms of fibromyalgia. They propose the potential mechanisms of action underlying saffron’s effect on fibromyalgia involve its anti-inflammatory and antioxidant effects, as well as its effects on the serotonergic system. There are several limitations to this study, including narrow inclusion criteria, and the short study period. As a comparative effectiveness study, a placebo arm was not included in the study design and future research to elucidate the size of the treatment effect for saffron in people with fibromyalgia is needed. A strength of the study was that it demonstrated equivalency for a low dose of saffron for this expensive herbal medicine. This study provided preliminary evidence on comparable efficacy of saffron and duloxetine in treatment of fibromyalgia. Given the outcomes of the study, future clinical trials that investigate the mechanism of therapeutic effect are warranted, and the safety of saffron as an adjuvant to other pharmaceutical medications should also be investigated.

**A comparison between the effects of ginger, pyridoxine (vitamin B6) and placebo for the treatment of the first trimester nausea and vomiting of pregnancy (NVP)**


Sixty to eighty per cent of women experience nausea and vomiting of pregnancy (NVP) or morning sickness in the first half of pregnancy. Although NVP has been linked to better pregnancy outcomes, it can have significant impacts on the social and daily functioning of women, and 10% of pregnant women require medication. The cause of NVP is still unknown but the relationship between human chorionic gonadotropin (HCG) and oestrogen has been proposed and pregnant women’s preferences for natural medicines have been reported. Accordingly, interest is high for natural therapies that provide relief for NVP and are safe and well tolerated. Two natural interventions previously explored include vitamin B6 and ginger. Ginger is a competitive antagonist for H3 receptors and it has clinical effect a few days after treatment for approximately 80% of women. The aim of the current study was to compare the effects of ginger to vitamin B6 and placebo for the treatment of NVP.

The study was a triple-blind random and consecutive control trial including women who were 6–16 weeks’ pregnant, had mild to moderate NVP and presenting to casualty from September 2012 to January 2015 to the Akbarabadi Teaching Hospital, Tehran, Iran. Exclusion criteria included NVP needing hospitalisation, lack of acceptance of herbal medicine, gastrointestinal or other pathological disorders, or allergy to ginger or vitamin B6. Subjects were allocated to one of three groups: ginger (500 mg), B6 (40 mg) or placebo twice daily for four days. The primary endpoint was changes in the Rhodes Score at four days.

In total, 77 women completed the study (28 in the ginger group, 26 in the Vitamin B6 group and 23 in the placebo group). At the beginning of the trial, the women did not show significant difference in age, parity, gestational age, level of education or severity of symptoms. An endpoint, a statistically significant improvement, was found for both B6 and ginger compared to placebo for reducing intensity frequency and distress of nausea, vomiting and
retching. In a per group analysis of change over time, ginger was more effective for reducing severity of nausea and amount of vomiting, and B6 was more effective for reducing retching and distress of vomiting. A limitation of this study was that the method of allocating participants to the intervention groups (B6, ginger and placebo) was not clearly explained. The researchers state group allocation was conducted using a mixture of consecutive assignment and randomisation. Consecutive assignment means that the confounding characteristics of the participants, such as parity, term of pregnancy, age, reproductive history were not controlled and that the outcomes may not be explained by the treatments alone.

In previous systematic reviews, ginger has been found to be an effective and safe medication to reduce the frequency and severity of nausea and vomiting in NVP. However, it is important to note that a maximum safe dose in pregnancy is not clear, and while the current and previous research indicates it is as effective as B6 in reducing symptoms of NVP, more studies are required. Future research is required to assess optimal dose for each symptom of NVP.

Effect of garlic supplementation on serum C-reactive protein


Garlic is one of the oldest known medicinal plants, and it contains several bioactive constituents, such as allicin, which are known to have anticoagulant, antithrombotic, antioxidant, hypoglycemic, hypcholesterolaemic and hypotensive effects. In addition, it is shown that garlic has antimicrobial, anticarcinogenic, anti-asthmatic, immunomodulatory and prebiotic effects. Allcin and other sulphur-containing compounds are believed to be responsible for the anti-atherosclerotic effects of garlic, while the non-sulphur-containing compounds, including polyphenols, are believed to have antioxidant properties that may provide benefit for inflammatory and metabolic disorders. The aim of the review was to assess the anti-inflammatory benefits of different forms of garlic using C-reactive protein (CRP) levels.

Databases including Scopus, PubMed, Cochrane Library and Google Scholar were searched through to January 2018. The review included randomised controlled trials that investigated garlic in any form (raw, aged, powder, tablet and capsule) and CRP. Studies were excluded if they were not randomised or did not have a control group, lacked enough data for statistical pooling or did not report CRP values. Predefined subgroup analyses were conducted including duration of study, intervention dose, baseline CRP and quality of studies. Weighted random effect meta-regressions were performed to determine the effects of potential moderators like garlic dosage and baseline CRP. The funnel plot test was used to assess publication bias.

Supporting Women’s Health Naturally
So you can get on with life

A Women’s cycle has been associated with the Moon for centuries. Each phase of a women’s cycle is required to be treated differently as does each phase of her life.

Our Chinese Herbal Gynaecology range - Red Moon - offers an easy to prescribe range of formulas to address the most common problems associated with both the reproductive years and during Menopause.

- No gelatin
- No added sugar
- No artificial flavours or colours
- High Strength 8:1
- Natural film coated tablets
In total, nine studies were included for meta-analysis, ranging from 2 to 48 weeks, with a median of 12 weeks. Sample size ranged from five to 28 subjects, with a total sample size of 563 (183 in intervention groups and 180 in control groups). Garlic dosing ranged from 250 to 3,600 mg/day with the median of 2,100 mg/day. The age of participants ranged from 25 to 75 years, and five out of nine studies involved patients with chronic disease (TD2M, or coronary artery disease). Baseline CRP varied from 0.21 to 6.7 mg/L with a median of 2.4 mg/L. Six studies were classified as high methodological quality.

Compared with the controls, garlic intake significantly reduced the concentrations of serum CRP by 0.8 mg/L (p = 0.02) with the evidence of heterogeneity among studies. Heterogeneity included variations in interventions (aged garlic powder, allicin with or without other co-supplements such as arginine, B12, B6, or CoQ10), and subject characteristics (for example, race, lifestyle, chronic disease). Subgroup and meta-regression analyses revealed supplementation with garlic produced a significant reduction of serum CRP among subjects with high supplemental doses or higher baseline CRP. Garlic significantly lowered CRP by 0.82 mg/L (p < 0.001) among studies with a daily garlic dose ≥1,200 mg/day and by 2.44 mg/L (p = 0.002) among studies with baseline CRP ≥2 mg/L, meaning trials with higher dose garlic or higher baseline CRP showed a significant decrease in mean effect sizes of serum CRP, compared with shorter periods or subjects with lower serum CRP. The latter finding is clinically significant, since it has been shown that in patients with intermediate cardiovascular disease risk, hsCRP levels ≥2 mg/L may reclassify patients into the high risk category. The mechanism by which garlic compounds exert anti-inflammatory effects is not completely known, but may be related to their ability to attenuate the production of inflammatory cytokines via the NF-κB pathway.

This meta-analysis has several limitations including the small sample sizes of the included studies, the inclusion of studies with combined therapy (where garlic was administered with conventional medicines or other supplements) and heterogeneity of studies. Further large and well-designed randomised controlled studies are warranted to further investigate these findings.

**Effects of Curcumin longa on the metabolic parameters of fatty liver disease**


Non-alcoholic fatty liver disease (NAFLD) is a chronic disease that affects approximately 30% of the adult population in Western countries. The disease results from accumulation of fat around liver cells and is associated with diabetes, dyslipidaemia, obesity, cardiovascular disease and metabolic syndrome. The first-line therapy for NAFLD is lifestyle intervention, with weight loss being the key intervention. However, less than 10% of patients with NAFLD achieve the weight loss necessary to induce regression of fibrosis. Curcumin is a natural polyphenol that has antioxidant, anti-inflammatory, antimicrobial and anti-carcinogenic effects. Several small clinical trials have demonstrated positive outcomes and a potential benefit for people with NAFLD; however, the precise mechanisms of action have not yet been established. The aim of the current meta-analysis was to assess efficacy and safety of curcumin in patients with NAFLD.

Databases including PubMed, EMBASE and the Cochrane Library were searched up to March 2018. The review included studies that were randomised, placebo-controlled, with patients aged over 18 years, and NAFLD (grades 1 to 3) assessed via liver ultrasound. Studies that compared curcumin to placebo were included. The Cochrane risk bias tool was used to evaluate study quality. Efficacy was calculated using changes in biomarkers including serum lipid biomarkers (LDL-C, total cholesterol, HDL-C, and triglycerides) and metabolic biomarkers (HbA1c, insulin and HOMA-IR), liver function biomarkers (ALT and AST) and weight. The meta-analysis was completed using a random effects model.

In total, four RCTs were included with a total of 229 NAFLD patients (115 curcumin and 114 placebo). The number of participants ranged from 20 to 87 and the dosing of curcumin ranged from 500–1,000 mg/day curcumin and 3,000 mg/day turmeric). Duration of supplementation ranged from eight weeks to six months. All studies were parallel group and had high quality according to the Cochrane risk bias tool.

When the data was pooled, curcumin was found more likely to lower LDL-C, triglycerides, fasting blood glucose, HOM-IR, weight and AST levels compared with placebo, and the difference was statistically significant. One RCT reported adverse events in the curcumin group.

The authors propose that curcumin may have multiple mechanisms of action that make it beneficial for treatment of NAFLD, including its ability to decrease expression of HMG-CoA reductase, and to decrease lipogenesis and adipogenesis. Furthermore, curcumin may improve insulin sensitivity, and decrease production of inflammatory cytokines, thereby reducing hepatic apoptosis. Another potential mechanism is via curcumin’s role on gut microbiota. The oral bioavailability of curcumin is very low, and curcumin reaches the gut almost unaltered, where it thereby exerts prebiotic effects and could potentially improve metabolic parameters of NAFLD.

This meta-analysis provides an overview into the use of curcumin for NAFLD. While the authors recognise that curcumin may have potential benefits on metabolic parameters of NAFLD, it is noted that there are several limitations to this study. Limitations include small sample size, population characteristics, and curcumin dose and duration of supplementation in the studies included. More RCTs with larger sample sizes are required to confirm findings of this meta-analysis.
CPE points

The AJHNM-based CPE questionnaire system is a voluntary system designed to assist members in the accumulation of NHAA CPE points. Questions are divided into the appropriate subject categories (herbal medicine and medical science) and each question refers to an article in this issue of the Australian Journal of Herbal and Naturopathic Medicine. Points accumulated through completion of these questions should be recorded in the NHAA CPE diary. Each completed question is worth one mark in the relevant category. Your completed CPE diary should be returned with your membership renewal at the end of the calendar year. For further information, please see the NHAA CPE Members’ Manual on the NHAA website www.nhaa.org.au.

CPD — MedJourn

With reference to the study investigating the role of the Mediterranean diet (MD) and stroke risk, which of the following statements is incorrect?:

• Risk of stroke was significantly reduced with greater adherence to the MD across the whole study population.
• Moderate adherence to MD was associated with a significant reduction in stroke risk in women but not men.
• A significant risk reduction was observed in both high and low cardiovascular risk subgroups.
• Vegetable and moderate alcohol intake were associated with the stroke risk reduction.

With reference to the Cochrane review on omega-3 supplementation during pregnancy, which of the following statements is correct?:

• Omega-3 supplementation was associated with reduced preterm birth (<37 weeks) and early preterm birth (<34 weeks).
• Increased risk of low birthweight babies was reported for omega-3 supplementation.
• Perinatal outcomes revealed possible reduced risk of perinatal death and reduction in neonatal care admissions.
• Omega-3 supplementation was possibly associated with prolonged gestation (>42 weeks).

Regarding the follow-up study of ART-conceived adolescents and arterial hypertension, which of the follow statements is incorrect?:

• 24-hr systolic BP and diastolic BP was markedly higher in the ART group than control.
• Eight of the ART adolescents met the criteria for diagnosis of arterial hypertension.
• Premature vascular ageing persisted in the ART-conceived adolescents at the five-year follow-up.
• Endothelial dysfunction, decreased vascular stiffness, and structural heart disease may be related to the vascular ageing.

MedPlant

Regarding the study investigating ginger and vitamin B6 for treatment of the first trimester nausea and vomiting of pregnancy (NVP), which of the following statements is correct?:

• After four days of supplementation, ginger was more effective than placebo for reducing severity of nausea.
• After one day, B6 was more effective than placebo for reducing severity of nausea and vomiting.
• After four days, ginger was more effective than placebo for reducing retching and distress of vomiting.
• After four days, ginger was more effective for reducing severity of nausea and amount of vomiting.

Regarding the study comparing the efficacy of saffron with duloxetine for the treatment of fibromyalgia, which of the following is true?:

• At the end of the trial, HRSD scores had only decreased in the duloxetine group.
• Saffron was more effective than placebo for reducing FIQ and BPI scores.
• Saffron was equivalent to duloxetine for improved mental and physical symptoms associated with fibromyalgia.
• There were statistically significant differences in adverse effects detected in the two treatment arms.

With refernce to the study investigating Rhodiola rosea supplementation on mental performance, physical capacity and oxidative stress biomarkers in healthy men, which is correct?:

• Rhodiola ingestion significantly increased plasma total antioxidant capacity.
• Rhodiola ingestion did not improve some psychomotor test scores.
• The current study showed significant changes in salivary cortisol in healthy individuals are exercise.
• The results of the current study demonstrate that rhodiola ingestion significantly improves physical performance in young men.

With regard to the meta-analysis studying the effect of garlic supplementation on serum C-reactive protein, which of the following is true?:

• Subgroup analysis demonstrated that garlic did not significantly lower CRP in studies using ≥1,200 mg/day.
• Eleven studies were included in the meta-analysis, with study periods ranging from 3 to 41 weeks.
• The median garlic dose used in studies was 1,200 mg/day.
• Compared with the controls, garlic intake significantly reduced serum concentrations of CRP by 0.8 mg/L.
With regard to the meta-analysis studying the effects of curcumin on the metabolic parameters of fatty liver disease, which is correct?:

- Curcumin was more likely to lower LDL-C, triglycerides, fasting blood glucose, HOM-IR, weight and AST levels compared with placebo.
- Five RCTs were included in the meta-analysis.
- Dosing of curcumin ranged from 200 mg/day to 3,000 mg/day.
- A random effects model was not used to complete the meta-analysis.

In the study investigating the efficacy of saffron for macular degeneration, which is not correct?:

- Ninety-seven participants completed the trial.
- Mean BCVA improved 0.69 letters (p=0.001) and mean-pooled mfERG latency reduced 0.17 ms (p=0.04) on saffron compared to placebo.
- Mean BCVA improved 0.73 letters (p=0.006) and mean pooled mfERG response density improved 2.8% (p=0.038).
- There were significant differences in adverse effects occurrence between treatment arms.

In the meta-analysis reviewing efficacy and safety of green tea for NAFLD, which is correct?:

- Six studies with 256 participants were included in the qualitative study.
- Green tea produced a significant effect on high-density lipoprotein cholesterol concentrations.
- NAFLD diagnosis in the studies was not confirmed by ultrasonography.
- Green tea produced significant effects on alanine and aspartate blood concentrations.

MedJourn and MedPlant References


Iacovou M, Craig SS, Yelland GW, Barrett JS, Gibson PR, Muir JG. Randomised clinical trial: reducing the intake of dietary FODMAPs of breastfeeding mothers is associated with a greater improvement of the symptoms of infantile colic than for a typical diet. Ailment Pharmacol Ther 2018;48:1061–1073


Wei Z et al. The effects of curcumin on the metabolic parameters of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Hepatol Int 2018;1–12.
THE 2019 INTERNATIONAL CONGRESS ON
NATURAL MEDICINE
THE MOST SIGNIFICANT ANNUAL EVENT HELD IN THE NATURAL MEDICINE INDUSTRY
Saturday 8th - Monday 10th June | RACV ROYAL PINES RESORT, GOLD COAST.

YOUR INVITATION
Modern Epidemics: Practicing Tomorrow’s Medicine, Today
Translating New Science into Breakthrough Therapies
Chronic disease is spiralling out of control. Mood and neurological disorders, immune dysfunction, arthritis, fatigue, hormonal issues, and obesity have all increased in prevalence at an exponential rate over the past few decades. Unfortunately, the current medical management of many of these disorders is centred on symptomatic reduction, whilst the underlying drivers continue. However, recent scientific discoveries in the fields of inflammation, immunity, epigenetics and bioenergetics have elucidated the precise mechanisms of the root causes of modern diseases and identified novel means to correct them. It is time to translate this cutting edge science into clinical practice.

THE EVENT
In 2019, the Metagenics International Congress on Natural Medicine will assemble pioneering Thought Leaders, Researchers and Clinicians who are changing the way Natural Medicine is practiced, for an event not to be missed. Discover how newly identified inflammatory mediators are fuelling some of the most frequently presenting complaints. Learn which stealth drivers are at the root of chronic diseases. Find out about tomorrow’s standards in healthcare technology and patient care that can be applied today. Become one of a new wave of Practitioners armed with the tools and knowledge to free your patients from the burden of chronic disease.

2019 PRESENTER LINE-UP
Dr Jeffrey Bland
Dr Kara Fitzgerald
Nicole Bijlsma
Professor Amanda Salis

Join our Metagenics Facebook group to see more Congress presenters as they’re announced!

EARLY BIRD RATES
Early Bird price of $695.00 incl. GST. (normal price $795.00 incl. GST) each per person. (Same price applies in New Zealand.) Early Bird ends Wednesday 25th February, 2019 or if sold out prior.

Call 1800 777 648 (Australia)
or 0508 227 744 (New Zealand)
metagenics.com.au/events
SAVE THE DATE

JOIN US AT THE 7TH BIOCEUTICALS RESEARCH SYMPOSIUM, A THREE-DAY MASTERCLASS HIGHLIGHTING THE FUTURE OF PERSONALISED MEDICINE FOCUSSING ON MOOD, GENES AND COGNITION:

CONFIRMED INTERNATIONAL SPEAKERS

Dr Dale E Bredesen, (USA) Professor of Neurology
Dr Dale E Bredesen is internationally recognised as an expert in the mechanisms of neurodegenerative diseases such as Alzheimer’s disease. Dr Bredesen’s research has led to new insight that explains the erosion of memory seen in Alzheimer’s, and has opened the door to a new therapeutic approach. He has found evidence that Alzheimer’s disease stems from an imbalance in nerve cell signalling. Dr Bredesen will cover the mechanisms underlying the neurodegenerative process, and the translation of this knowledge into effective therapeutics for Alzheimer’s disease and other neurodegenerative conditions.

Dr Jay Lombard, (USA) Internationally Acclaimed Neurologist
Dr Jay Lombard is an internationally acclaimed neurologist, author, and keynote speaker who creates solutions for brain health and intractable neurological disorders. Dr Lombard integrates biological, psychological, and existential components in his holistic treatment approach. He is the co-founder and creator of Genomind, a precision medicine company utilising genetic testing to improve neuropsychiatric conditions, including Alzheimer’s, autism, and depression. Founder of TedMed, Jay Walker, describes Dr Lombard as “part Freud, part Sherlock Holmes.” Dr Lombard’s discoveries have been regarded by key opinion leaders as fundamentally shifting the paradigm of psychiatric medicine.

Ms Amanda Archibald, (USA) Registered Dietitian, Nutritionist and Public Health Advocate
Ms Amanda Archibald is a registered dietitian, nutritionist and public health advocate who has pioneered the combination of the science of nutrigenomics with the culinary arts. Amanda will draw particular attention to the mechanisms of food-gene relationships related to the core issues known to affect long-term health – inflammation, oxidative stress, blood sugar and fats, and gut health – while emphatically encouraging the discovery of taste and culinary treasure in the process. She will present an empowering new system for choosing, preparing and cooking ingredients for optimal long-term health based on a language recognised by DNA.

Dr Brandon Brock, (USA) Board Certified Chiropractic Neurologist, Family Nurse Practitioner and Nutritionist
Dr Brandon Brock has a passion for providing easy to comprehend skills that can be utilised in a clinical setting. He received the most outstanding functional neurology teacher of the year award from the ACA Council of Neurology for five years and twice from IAFNIR (International Association of Functional Neurology and Rehabilitation). Dr Brock will present his unique and integrated understanding of functional neurology blending nutrition, pharmacology, immunology and endocrinology to provide a comprehensive and multi-perspective approach to clinical presentations.

FIND OUT MORE Take advantage of limited time Early Bird rates! Go to: bioceuticals.com.au/education/events